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Liver cancers 
Liver cancer is one of the leading global health care issues. Primary liver cancers include 
hepatocellular carcinoma (HCC), cholangiocarcinoma and hepatoblastoma, the latter which is 
mainly observed in children. Focal nodular hyperplasia and hepatocellular adenoma are 
benign hepatocellular tumors that develop most frequently in women without cirrhosis (1). 
Other tumors observed in the liver, such as fibrosarcoma, angiosarcoma, leiomyosarcoma and 
lymphoma, are rare but have malignant potential. 
Around 90% of liver cancer patients are diagnosed with HCC, the fifth most frequent 
cancer and highly relevant to cancer related deaths worldwide (2, 3). Hepatitis B (HBV) and 
hepatitis C (HCV) viruses together with alcohol abuse, obesity-induced non-alcoholic 
steatohepatitis (NASH) and aflatoxin-B1 exposure are considered as the major causes for HCC, 
which show regional preferences. In parts of Asia and Africa, high incidence of HCC is linked 
to elevated HBV and aflatoxin-B1 prevalence (4). In western countries, the main causes are 
HCV, alcohol abuse and NASH (5, 6). 
Hepatocarcinogenesis is a complex pathological process that can take decades from 
tumor cell initiation to the final malignant tumor. Etiological factors mentioned above lead to 
chronic hepatitis, which gives rise to fibrosis and progression to cirrhosis around 10 years later 
(7). Cirrhosis chronically alters the liver microenvironment which potentiates the initiation and 
progression of HCC. During this process, the accumulation of aberrant genetic and epigenetic 
modifications elicits the dysregulation of signaling pathways. This in turn facilitates the 
transformation from the precancerous dysplastic hepatocytes into early HCC that ultimately 
progresses to malignant phenotypes. 
Wnt/β-catenin signaling 
The evolutionarily conserved Wnt signaling pathway is involved in both physiological and 
pathophysiological processes (8-10). Wnt signaling is triggered by Wnt ligands. These ligands 
are generated within the endoplasmic reticulum (ER), modified by palmitoylation by the Wnt 
acyl-transferase porcupine (PORCN) and shuttled by Wntless (WLS) from the Golgi to the 
plasma membrane where they can signal in an autocrine or paracrine manner (Figure.1) (11, 
12). Nineteen Wnt ligands have been identified in the human genome. Based on the 
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dependency of β-catenin to transduce the signal, Wnt signaling is subdivided into canonical 
Wnt/β-catenin pathway, the noncanonical planar cell polarity pathway, or the noncanonical 
Wnt/calcium pathway. In this thesis, we mainly focus on the canonical Wnt/β-catenin pathway, 
largely relevant to HCC. 
 
 
Figure.1 Wnts are lipid modified by PORCN in the ER and escorted by WLS from the Golgi to the plasma 
membrane for secretion. Figure adapted from reference Hausmann G, et al (11). 
Canonical Wnt/β-catenin signaling is normally turned off in tissues of adults with the 
exception of part of stem cell niches (13). Regulation of Wnt/β-catenin signaling is fine-tuned 
at both extracellular and intracellular levels. Extracellularly, Wnt ligands are captured by Wnt 
antagonists, such as secreted Frizzled-related proteins (SFRPs), dickkopf (DKKs) and the Wnt 
inhibitory factor (WIF) (14). Intracellularly, the cytosolic transcription factor β-catenin is tightly 
regulated by a multiprotein complex composed of the adenomatous polyposis coli (APC) 
tumor suppressor, scaffold proteins AXIN1, AXIN2 and AMER1, and the kinases GSK3 and CK1α. 
Kinase CK1α triggers the priming site at Ser45 of β-catenin allowing the subsequent 
phosphorylation at Thr41, Ser37 and Ser33 by GSK3. Then the β-transducin repeat containing 
protein (βTRCP) recognizes the phosphorylated β-catenin for subsequent proteolysis (14, 15). 
The overall effect is to maintain minimal levels of free cytosolic β-catenin (Figure.2).  
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Figure.2 The canonical Wnt/β-catenin signaling pathway. (A) In the absence of Wnt ligands, β-catenin is 
phosphorylated by a degradation complex consisting of GSK3β, CK1α, APC and AXIN1/AXIN2. Phosphorylated β-
catenin is targeted for proteasomal degradation after ubiquitination by the SCF protein complex. In the nucleus, 
the TCF/LEF transcription factor activity is repressed by TLE-1. (B) Activation of canonical Wnt/β-catenin signaling 
leads to the dissociation of the degradation complex. As a result, β-catenin accumulates in the cytoplasm and 
translocates into the nucleus, where it promotes the expression of target genes via interaction with TCF/LEF 
transcription factors and other proteins such as CBP, Bcl9, and Pygo. Both figure and text adapted from reference 
Pez F, et al (16). 
Wnt ligands initiate the signaling by binding with a member of the frizzled receptor (FZD) 
family and one of the low-density lipoprotein receptor-related protein 5/6 (LRP5/6) co-
receptors. Then the scaffolding proteins disheveled (DVL) and AXIN are recruited to the 
membrane, leading to the disassembly of the multiprotein β-catenin destruction complex (17) 
and subsequent accumulation of unphosphorylated β-catenin (active β-catenin) in the 
cytoplasm. The active β-catenin translocates to the nucleus (18) and binds transcription 
factors of the T-cell factor (TCF7, TCF7L1 and TCF7L2)/lymphoid enhancer-binding factor (LEF) 
family, triggering the transcription of downstream Wnt/β-catenin target genes (16, 19) 
(Figure.2). Thus, the mechanism underlying the regulation of canonical Wnt/β-catenin 
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signaling is complicated. Functional mutations of these related proteins could lead to the 
dysregulation of target gene transcription. 
Aberrant activation of Wnt/β-catenin signaling in hepatocellular 
carcinoma 
Inappropriate activation of Wnt/β-catenin signaling is critical in HCC (14, 16, 20-22). The 
central component transcription factor β-catenin shows nuclear accumulation in around 40%-
70% of HCC patients. Distinctive molecular or genetic alterations have been identified to 
stabilize β-catenin and to aberrantly trigger Wnt/β-catenin signaling, such as elevated level of 
upstream Wnt ligands or cell surface receptors and decrease of extracellular inhibitors [26]. 
In addition, frequently gain-of-function mutations are observed in exon3 of the CTNNB1 gene 
(encoding β-catenin) (15-25%) at the phosphorylation residues (23), which result in the 
expression of mutant β-catenin resistant to proteolytic degradation. Loss-of-function 
mutations of negative regulators are reported in AXIN1 (10.4%), AXIN2 (3.3%) and APC (1.4%) 
(24), evidently contrasting with the situation in colorectal cancer (CRC) where up to 80% of 
cancers display mutated APC (25, 26). Frameshift mutations or genomic deletions in these 
genes elicit the compromised function of the multiprotein complex to degrade β-catenin and 
is thus also related to enhanced Wnt/β-catenin signaling. 
The relative mutation frequencies of these various Wnt/β-catenin signaling elements are 
different in HCC as compared to other cancers, e.g. sporadic CRC. The reason underlying these 
disparities could be due to different etiology of HCC, such as HBV or HCV, which shows 
preference on the different type of mutations that arise in liver genomes as compared to other 
sites in the body (24, 27). It may also derive from the fact that in different organs, optimal 
cancer-driving Wnt/β-catenin signaling mutations may be substantially different, resulting in 
selection pressure for different types of mutations (25). 
Target Wnt/β-catenin signaling 
In light of the importance of aberrant activation of Wnt/β-catenin signaling in HCC, 
components involved in this pathway could be promising therapeutic targets for HCC therapy. 
After decades of extensive research to identify these Wnt/β-catenin signaling inhibitors, there 
have been numerous small molecules discovered that may possess this potential. In table 1, 
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we provide a summary of the reported Wnt/β-catenin signaling inhibitors tested in different 
tumor types. Some of these inhibitors target the upstream components of Wnt/β-catenin 
signaling including the porcupine protein, Wnt ligands, FZD receptors and co-receptors. 
Others aim at interfering with the intracellular signal transduction process by targeting DVL, 
AXIN, GSK3, CK1α or β-catenin itself, or affect its interaction with co-activators or 
transcriptional factors. Some of these inhibitors are currently undergoing clinical trials. 
Table.1 Wnt/β-catenin signaling inhibitors undergoing preclinical and clinical evaluation 
Targets Compounds Diseases Stage References 
Porcupine LGK974 
Pancreatic adenocarcinoma,  
BRAF mutant colorectal cancer 
head and neck squamous cell carcinoma 
Phase 1 (28) 
 IWPs Colon cancer Preclinical  
 Wnt-C59 
Mammary tumor 
Pancreatic cancer 
Preclinical (29, 30) 
 ETC-1922159 
Colorectal cancer 
Mammary tumor 
Teratocarcinomas 
Phase 1 (31) 
FZD1/2/5/7/8 
OMP-18R5 
(vantictumab) 
Breast cancer 
Lung cancer 
Pancreas cancer 
Colon cancer 
Phase 1 
 
(32) 
FZD7 sFZD7 HCC Preclinical (33) 
FZD8 OMP-54F28 
Liver cancers (HCC) 
Ovarian Cancer 
Pancreas cancer 
Solid tumor 
Phase 1  
 
(21) 
LRP6 Niclosamide Prostate; Breast Preclinical (34) 
 Silibinin Prostate; Breast  Preclinical (35) 
LRP5/6 Salinomycin 
breast, prostate, lung, gastric, osteosarcoma, 
HCC 
Preclinical (36-41) 
Wnt1 Anti-Wnt1 
HCC, CRC, Lung cancer, sarcoma, breast 
cancer, head-neck squamous cell carcinoma 
Preclinical (42-46) 
Wnt2 Anti-Wnt2 Melanoma, mesothelioma, lung caner Preclinical (47-49) 
Wnt10b Anti-Wnt10b head-neck squamous cell carcinoma Preclinical (46) 
Wnt ligands WIF-Fc/ SFRP-Fc HCC Preclinical (50) 
DVL NSC668036   (51) 
 3289-8625 Prostate cancer  (52) 
 FJ9 Melanoma, lung cancer  (53) 
Tankyrase/AXIN XAV939 CRC, neuroblastoma, breast cancer Preclinical (54-56) 
 IWR-1 CRC, prostate Preclinical (57) 
 JW55 CRC Preclinical (58) 
GSK3β DIFs Leukemia Preclinical (59-63) 
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HeLa 
CK1α Pyrivinium CRC Preclinical (64, 65) 
β-catenin 
phosphorylation 
CGK062 CRC, HCC, prostate cancer Preclinical (66) 
β-catenin 
ubiquitination 
Hexachlorophene CRC Preclinical (67) 
 Isoreserpine CRC Preclinical (68) 
β-catenin β-catenin siRNA HCC Preclinical (69) 
 BBI608 
Glioblastoma, CRC, HCC, gastric cancer, 
pancreas cancer, lung cancer 
Phase 1/2 (70) 
β-catenin/CBP ICG-001 
CRC, breast cancer, pancreatic cancer, head-
neck squamous cell carcinoma 
Preclinical (71-74) 
 PRI-724 
Pancreatic adenocarcinoma, leukemia, CRC, 
HCV-induced cirrhosis, solid tumor 
Phase 1  
β-catenin/TCF 
PKF115-548 
PKF222-815 
CGP049090 
FH535 
HCC, CRC, lung cancer Preclinical (75-78) 
cyclooxygenases NSAIDS CRC Preclinical (79-82) 
β-catenin/E-
cadherin 
Vitamin 
derivatives 
CRC Preclinical (83) 
β-catenin 
nuclear export 
Peg-IFN HCC Preclinical (84) 
 
Aim of the thesis 
During last decades, a tremendous progression of knowledge and understanding about liver 
cancer development has been witnessed. The progression in clinical technology has been 
instrumental for early detection. In addition, the Barcelona clinic liver cancer (BCLC) staging 
and treatment model that also takes into account remaining liver functionality and general 
health of the patient, has been broadly endorsed worldwide. These achievements facilitate 
the early diagnosis and enable more efficient treatment strategies to improve the outcome of 
HCC patients. Nevertheless, HCC related mortality is still high worldwide. Given that HCC 
individuals show extensive phenotypic and molecular heterogeneity, it is important to identify 
the molecular features and genomic traits of HCC patients, thus aiding reasonable 
stratification and optimal personal treatment decisions. 
As one of the critical contributing factors to HCC growth, aberrant activation of Wnt/β-
catenin signaling derives from a variety of molecular alterations involved in this pathway, 
especially mutations of β-catenin and AXIN1. As illustrated in Table 1, a variety of drugs 
targeting Wnt/β-catenin signaling have been developed, but most of them have not been 
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thoroughly tested for liver cancer. In the current thesis, our first aim is to explore the 
effectiveness of two classes of drugs in a panel of HCC cell lines, i.e. an extracellular Wnt 
secretion inhibitor and cytosolic tankyrase inhibitor. The second aim is to compare the 
response and sensitivity for these inhibitors depending on the specific β-catenin signaling 
defect present in these HCC cell lines, i.e. CTNNB1 or AXIN1 mutations. 
Our third aim is to achieve a better understanding the mechanism through which AXIN1 
mutations contribute to HCC cell growth. As a critical negative regulator of Wnt/β-catenin 
signaling, mutation or deletion of AXIN1 is expected to support tumor growth by enhancing β-
catenin signaling. However, AXIN1 mutations were shown to not cause a robust induction of 
β-catenin target genes in liver cancers (3, 85). Hence, the specific role of AXIN1 mutation in 
reprogramming Wnt/β-catenin signaling in liver cancers remains under debate. Lastly, we also 
intend to find new potential molecular targets regulating Wnt/β-catenin signaling in HCC. 
Outline of this thesis 
In chapter 1, we have provided a general introduction of Wnt/β-catenin signaling and its role 
in the initiation and progression of liver cancers. In chapter 2, we review how aberrant 
activated Wnt/β-catenin signaling interacts with the HCV viral components and potentiates 
the progression from hepatitis C to HCC. In chapter 3, we investigate the dependency of 
extracellular Wnt secretion to support growth in 9 HCC cell lines characterized by mutations 
in either CTNNB1, AXIN1 or no obvious mutation in a β-catenin signaling related component, 
also in comparison with CRC cell lines. In chapter 4, we use the same cell line panel to explore 
whether the inhibition of tankyrase, by endorsed inhibitors XAV939 as well as IWR-1, stabilizes 
AXIN1/2 and attenuates Wnt/β-catenin signaling in HCC cells. We further compare the 
contribution of AXIN1 and AXIN2 in this process. In chapter 5, we test the expression levels of 
serine-threonine kinase receptor-associated protein (STRAP) in patient HCC tissues and 
investigate its function in regulating Wnt/β-catenin signaling activity in our panel of HCC cell 
lines. In a related project (chapter 6), we describe a novel approach to support the 
identification of Familial Adenomatous Polyposis carriers among children with 
hepatoblastoma tumors employing β-catenin immunohistochemical staining and mutation 
analysis. 
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The novel insights derived from this thesis will be summarized and discussed in chapter 
7 and chapter 8, which will provide a better understanding of Wnt/β-catenin signaling in liver 
cancers and experimental evidence for future stratification and optimal treatment decision of 
patients carrying Wnt-driven liver cancers. 
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Abstract 
Hepatitis C virus (HCV) infection is one of the leading causes for hepatocellular carcinoma (HCC) 
worldwide, but the mechanistic basis as to how chronic HCV infection furthers the HCC 
process remains only poorly understood. Intriguingly, accumulating evidence indicates that 
HCV core and nonstructural proteins provoke activation of the Wnt/β-catenin signaling 
pathway, whereas the evidence supporting a role of Wnt/β-catenin signaling in the onset and 
progression of HCC is compelling. Convincing molecular explanations as how expression of 
viral effectors translate into increased activity of the Wnt/β-catenin signaling machinery are 
still largely lacking, hampering design of rational strategies aimed at preventing HCC. 
Furthermore, how such increased signaling is especially associated with HCC oncogenesis in 
the context of HCV infection remains obscure as well. Here we review the body of 
contemporary biomedical knowledge on the role of Wnt/β-catenin pathway in the 
progression from chronic hepatitis C, to cirrhosis and HCC and explore potential hypotheses 
as to the mechanisms involved. 
Keywords: Hepatocellular carcinoma; Wnt/β-catenin signaling; hepatitis C virus 
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Introduction 
HCV is estimated to infect up to 2% of the global population (around 180 million people 
worldwide) [1] with approximately 3-4 million new infections each year [2, 3]. Following 
infection, 60%-80% of affected individuals eventually develop chronic hepatitis [4]. After 
around 10 years of infection, 5%-10% of these chronically infected patients progress to 
cirrhosis [5]. In addition to the high mortality associated with advanced cirrhosis per se, 
annually another 2.0%-6.6% of cirrhotic patients with HCV infection progress to HCC [6, 7]. 
Understanding the details as to how HCV infection can promote the HCC process is thus of 
critical importance for the rational design of novel avenues aimed at the prevention and 
treatment of HCC. 
Distinct from hepatitis B virus (HBV), a DNA virus that can integrate into the human 
genome and thus directly provoke genomic alterations potentially leading to cancer [8], HCV 
is a RNA virus lacking a DNA intermediate phase in its life cycle and therefore its infection of 
liver cells is not associated with damage to the host genetic material per se [9]. Hence, the 
tumor promoting potential of HCV derives from indirect interaction with the hepatocyte 
genome. However, other pathogens with a similar infection route are less clearly associated 
with progression towards HCC, compare for instance hepatitis E virus infection. It thus appears 
that HCV has specific properties that promote further hepatocyte transformation. 
The Wnt/β-catenin pathway is an attractive candidate to mediate the HCV-specific 
effects leading to hepatocyte oncogenic transformation. Activation of this pathway is clearly 
contributing to hepatocarcinogenesis as indicated by the detection of recurrent genetic 
mutations of Wnt/β-catenin signaling pathway components in HCC that appear especially 
frequent in HCV-related tumors. Intriguingly, HCV-derived viral proteins appear to be capable 
of autonomous activation of Wnt/β-catenin signaling, although the underlying molecular 
mechanisms remain poorly understood. Here we explore potential hypotheses explaining 
these effects and summarize documented interactions of Wnt/β-catenin signaling 
components in HCC patients with HCV infection. We propose that the Wnt/β-catenin signaling 
pathway constitutes a rational target for the prevention and treatment of HCV-associated HCC. 
 
Wnt/β-catenin signaling 
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Wnt/β-catenin signaling is a pivotal morphogenetic pathway and accordingly associated with 
a host of physiological and pathophysiological processes, including embryonic patterning, cell 
proliferation, differentiation, angiogenesis and especially cancer [10-12]. Wnt signalling is 
initiated by binding of Wnt ligands to their cognate receptors. These Wnt ligands are 40kDa 
cysteine-rich glycoproteins [13], which following synthesis and primary glycosylation on the 
endoplasmic reticulum are palmitoylated by Wnt acyl-transferase porcupine protein in the 
Golgi apparatus. Secretion of Wnts then requires the evenness interrupted/wntless/G 
protein-coupled receptor 177 (Evi/Wls/GPR177), which shuttles palmitoylated Wnts to the 
plasma membrane, where they are released by the cell and initiate autocrine or paracrine 
signaling. Hitherto, nineteen Wnts have been identified in the human genome [14], and 
because annotation of Homo sapiens DNA is now quite complete it is unlikely further Wnt 
paralogues will be discovered. Wnts can provoke different modes of cellular signaling, either 
mediated by β-catenin or independent of this protein. According to the dependence on β-
catenin for provoking cellular effects, Wnts are classified into canonical (β-catenin-dependent) 
and non-canonical (β-catenin-independent) subgroups [15, 16]. In this review we shall focus 
on the canonical Wnts, as these are most associated with HCC in general and HCV-infection 
associated HCC in particular. 
Except for several stem cell niches, canonical Wnt/β-catenin signaling is typically not 
active in tissues of adult individuals [17], despite constitutive production of Wnt ligands. This 
is a result of the action of a range of Wnt antagonists, such as secreted Frizzled-related 
proteins (SFRPs), dickkopf (DKKs) and the wnt inhibitory factor (WIF) [18]. In this non-signaling 
state, cytosolic β-catenin is continuously phosphorylated at Ser33, Ser37, Thr41 and Ser45 
residues located in exon3 by a multiprotein complex consisting of adenomatous polyposis coli 
(APC), AXIN, glycogen synthase kinase-3β (GSK3β) and casein kinase 1 (CK1). These 
phosphorylations cause β-catenin to be recognized and poly-ubiquitinated by the β-transducin 
repeat containing protein (βTrCP) followed by β-catenin degradation in the proteasome [18, 
19]. The overall effect is that minimal free cytosolic β-catenin is available for nuclear signaling 
and thus Wnt-mediated gene transcription is absent under normal conditions. 
Upon binding of Wnt ligands to a complex consisting of the frizzled receptor (FZD) and 
co-receptors, which include the low-density lipoprotein receptor-related protein 5/6 (LRP5/6), 
the scaffolding protein disheveled (DVL) is recruited to the membrane, an event that in turn 
Chapter 2 
28 
 
causes the disassembly of the multiprotein β-catenin destruction complex. This results in 
rescue of β-catenin from proteasomal degradation and thus the accumulation of β-catenin in 
the cytoplasm, eventually causing β-catenin translocation to the nucleus [20]. In the nucleus, 
β-catenin binds transcription factors of the T-cell factor (TCF7, TCF7L1 and TCF7L2) 
4/lymphoid enhancer-binding factor (LEF) family, triggering transcription of downstream Wnt 
target genes, including CYCLIND1, AXIN2, C-MYC, RING FINGER PROTEIN 43 (RNF43) and 
ZINC/RING FINGER PROTEIN 3 (ZNRF3) [21, 22]. RNF43 and ZNRF3 are two closely related 
transmembrane E3 ligases, which remove surface FZD receptors by promoting their 
endocytosis [23]. This E3 ligase activity is in turn negatively modulated by R-spondins (RSPO) 
and the leucine-rich repeat-containing G-protein coupled receptor 4/5/6 (LGR4/5/6) that 
sequestrate RNF43 and ZNRF3 from FZD receptors by forming a tripartite complex [24]. Hence 
regulation of Wnt target gene transcription is complex allowing for extensive regulation but 
also for mechanisms leading to deregulation of target gene transcription in pathophysiology. 
Further complexity is added by the role of β-catenin in cell-cell adhesion where it acts, 
independent of its transcriptional activity, by forming a complex with cadherins and facilitating 
the formation of cellular junctions between adjacent hepatocytes. The β-catenin captured in 
these cell-adhesion complexes represents a dynamic pool of β-catenin capable of nuclear 
signaling following several stimuli. One of these stimuli is β-catenin tyrosine phosphorylation 
by receptor tyrosine kinases activated by growth factors produced by epithelial as well as 
stromal cells. In particular, phosphorylation of β-catenin residue Tyr654 results in its release 
from cadherins and an increase in TCF-mediated transcriptional activity [25-28]. Furthermore, 
the adherence pool of β-catenin also appears to be under indirect control of Wnt signaling 
itself. Upon activation of canonical Wnt/β-catenin signaling, the suppression of GSK3β leads 
to the upregulation of SNAIL [29]. As SNAIL is a repressor of the CDH1 gene encoding E-
cadherin [30, 31], this will lead to reduced E-cadherin production. Diminished E-cadherin 
causes the dissociation of the complex and subsequent internalization of β-catenin and 
accumulation of β-catenin in the perinuclear endocytic recycling compartment which 
promotes translocation to the nucleus to activate Wnt/β-catenin signaling [32, 33]. Hence 
pathogens can also provoke β-catenin signaling by disrupting intercellular junctions, in 
addition to direct effects on elements of the Wnt signaling cascade involved in regulating β-
catenin-mediated transcription. 
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Aberrant activation of Wnt/β-catenin signaling during HCC 
Important in the context of potential modulation by HCV infection in relation to HCC is that 
aberrant signal transduction in general and β-catenin signaling in particular, is one of the key 
characteristics of hepatocarcinogenesis [34]. Functional deregulation of Wnt/β-catenin 
signaling is reported frequently in HCC strongly suggesting that this pathway is important in 
this tumor type. Various genetic and molecular alterations have been identified to be pro-
oncogenic in a variety of settings, and have as a common denominator that they stabilize β-
catenin thus provoking enhanced transcriptional activity of Wnt target genes. Table 1 
summarizes the relative mutation frequency of Wnt/β-catenin signaling elements in HCC 
patients. Employing HCC cohorts from different countries, the most prevalent are activating 
mutations in CTNNB1 (encoding β-catenin) followed by loss-of-function mutations in AXIN1, 
AXIN2 and APC. The relative mutation frequencies of these various Wnt/β-catenin signaling 
elements are different in HCC as compared to other cancers, e.g. sporadic colorectal cancer. 
The reason why these differences emerge may result from different etiology of HCC and thus 
the type of mutations induced in liver genomes as compared to other sites in the body, but 
may also derive from the fact that in different organs, optimal cancer-driving Wnt/β-catenin 
signaling mutations may be substantially different, resulting in selection pressure for different 
types of mutations [35, 36]. As indicated in Table 1, in HCCs around 22.1% harbor specific gain-
of-function mutations of CTNNB1. Missense, insertion or partial deletions within CTNNB1 exon 
3 lead to the generation of a mutant β-catenin protein preventing the proper phosphorylation 
of amino acids Ser33, Ser37, Thr41 and Ser45 resulting in compromised degradation and thus 
stabilization of β-catenin in the cytoplasm. Less frequently, loss-of-function mutation of AXIN1, 
AXIN2 or APC is found in 10.4%, 3.3% and 1.4% of HCCs respectively, evidently contrasting 
with the situation in colorectal cancer where up to 80 % of cancers display mutated APC [36, 
37]. Frameshift or deletion in these genes yields impaired ability of the destruction complex 
to degrade β-catenin and is thus also associated with enhanced Wnt/β-catenin signaling. 
Overexpression of upstream ligands or cell surface receptors and reduction of extracellular 
inhibitors have been reported to stimulate activation of this pathway in HCC as well [38]. Thus 
evidently, at some stage in the progression towards full-blown HCC, acquisition of increased 
Wnt/β-catenin signaling provides liver cancer cells a relative advantage over cells not having 
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such mutations. Here we shall argue that especially HCV infections create the conditions which 
allow pre-carcinogenic cancer cells to exhibit such enhanced Wnt/β-catenin signaling. 
High frequency of CTNNB1 mutation in HCV related HCC 
HCV infection presents a substantial clinical challenge, for which only direct anti-viral 
medication appears a suitable solution [75]. If left untreated or not timely-recognized, 
persistent HCV infection causes immune-mediated chronic liver damage and compensatory 
hepatic regeneration by inducing cell proliferation and thus creates a microenvironment 
permissive for the induction of genetic alterations to the hepatocyte genome [76]. Following 
HCV infections, genetic abnormalities accumulate relatively slowly during the sequence of 
chronic hepatitis and increased cirrhosis that finally progresses to HCC. Consequently, the 
selective growth advantage provided to hepatocytes with a malignant phenotype eventually 
facilitates the development of phenotypically and genetically heterogeneous HCC [77]. As one 
of the principal proto-oncogenes in HCC development, the relatively high frequency of 
CTNNB1 mutations in HCV-related HCC is especially striking, in the view of the relative absence 
of such mutations in HBV-related liver cancers but also in the view of their paucity in not-
virally associated HCC (Table 2). Indeed, around 26.7% of HCV-related HCC harbor a CTNNB1 
mutation, which is much higher than that observed in HBV-associated HCC (11.6%) or that 
observed in total non-virally-associated HCC (21.2%). Furthermore, we noticed that, different 
from colorectal cancers which mainly show Thr41 and Ser45 mutations [36], HCV-related HCC 
shows a preference for CTNNB1 mutations from Asp32 to Ser37 residues [45, 47, 49, 59, 68, 
70, 71] (Fig.1). Recently, a genotype-phenotype correlation was shown for CTNNB1 mutations, 
suggesting that activating mutations occurring at the Asp32 to Ser37 residues lead to higher 
signaling levels than mutations at Thr41 and Ser45 [39]. This may partially explain the 
preference. It also could be attributable to the mutagenic dose demanded to induce HCC.  
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Table 1. Genetic mutation in components of Wnt/β-catenin pathway in HCC 
Reference Patient N Mutant samples N(%) Region 
  CTNNB1 AXIN1 AXIN2 APC  
Rebouissou et al.[34] 373 146(39) NA NA NA France, Spain, Italy 
Hirotsu et al.[35] 9 2(22.2) NA NA NA Japan 
Schulze et al.[36] 243 95(37.4) 27(11.1) 3(1.2) 4(1.6) France, Italy, Spain 
Kan et al.[37] 88 14(15.9) 4(4.5) 2(2.3) 2(2.3) China 
Kitao et al.[38] 134 27(20.1) NA NA NA Japan 
Ding et al.[39] 156 15(9.6) NA NA NA China 
Tornesello et al.[40] 67 10(14.9) NA NA NA Southern Italy 
Cleary et al.[41] 87 20(22.9) NA NA NA Canada, NC 
Guichard et al.[42] 125 41(32.8) 19(15.2) NA 2(1.6) France 
Lachenmayer et al.[43] 90 29(32.2) NA NA NA USA, Netherlands, Italy, Spain, Germany 
Li et al.[44] 139 28(20.1) NA NA NA USA, Netherlands, China 
Cieply et al.[45] 32 9(28.1) NA NA NA USA 
Bengochea et al.[46] 62 16(25.8) NA NA NA Thailand, France 
Austinat et al.[47] 40 10(25) 2(5) NA NA Germany 
Kim et al.[48] 36 1(2.8) 9(25) NA NA Korea 
Zucman-Rossi et al.[49] 45 18(40) 5(11.1) NA NA France 
Boyault et al.[50] 120 34(28.3) 13(10.8) NA NA France 
Zucman-Rossi et al.[51] 96 12(12.5) NA NA NA France 
Park et al.[52] 81 13(16) 5(6.2) NA NA Korea 
Ishizaki et al.[53] 89 10(11.2) 13(14.6) 9(10.1) NA Japan 
Cui et al.[54] 34 15(44.1) NA NA NA China 
Edamoto et al.[55] 100 24(24) NA NA 0 Japan, Switzerland 
Taniguchi et al.[56] 73 14(19.2) 7(9.6) 2(2.7) NA UK 
Wong et al.[57] 60 7(11.7) NA NA NA China 
Mao et al.[58] 262 37(14.1) NA NA NA Taiwan 
Cui et al.[59] 34 15(44.1) NA NA NA China 
Laurent–Puig et al.[60] 137 26(19) 12(8.8) NA NA France 
Devereux et al.[61] 62 5(8.1) NA NA NA China 
Hsu et al.[62] 434 57(13.1) NA NA NA Taiwan 
Satoh et al.[63] 87 0(0) 5(5.7) NA NA Japan 
Huang et al.[64] 22 9(41) NA NA NA Japan, Switzerland 
Legoix et al.[65] 119 21(17.6) NA NA NA France 
Terris et al.[66] 73 14(19.2) NA NA NA France 
Kondo et al.[67] 38 9(24) NA NA NA Japan 
Nhieu et al.[68] 35 12(34.3) NA NA NA France 
Miyoshi et al.[69] 75 14(18.7) NA NA NA Japan 
de La Coste et al.[70] 31 8(25.8) NA NA NA France 
Total 3788 837(22.1) 121(10.4) 16(3.3) 8(1.4)  
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Mutations at Ser45 require the selective duplication of the mutated allele as second 
activating hit, whereas only one activating hit for mutations at the Asp32 to Ser37.Although 
CTNNB1 mutation appear a late stage event in the progression to HCC [56], the high rate of 
CTNNB1 mutations observed may be directly and causally related to the HCV infectious 
process as in vitro studies show that both acute and chronic HCV infections provoke 
specifically CTNNB1 mutations, in hematological model systems and HCCs [78]. Evidently, 
clarifying the relationship between infection with a non-integrating virus and subsequent 
CTNNB1 mutations may prove exceedingly useful for designing strategies aimed at preventing 
HCV-associated HCC. 
Table 2. Comparison of CTNNB1 mutation in subtypes of HCC 
References CTNNB1 mutant samples N(%) 
Mutation 
type 
Amino acid Region 
 HCV HBV NV    
Hirotsu et 
al.[35] 2/5(40) 0/1(0) 0/3(0) Missense Gly34, His36 Japan 
Kitao et 
al.[38] 12/55(21.8) 4/34(11.8) 11/44(25) NA NA Japan 
Ding et al.[39] NA 12/110(10.9) 3/46(6.5) Missense 
Asp32,Gly34, Ser37, 
Thr41,Ser45 China 
Tornesello et 
al.[40] 10/57(17.5) 0/10(0) NA Missense 
Asp32, Ser33,Gly34 
Ile35, Ser37, Ser45 Southern Italy 
Kan et al. [37] NA 12/81(14.8) NA Missense 
Asp32, Ser33,Gly34 
Ile35, Ser37, Thr41, 
Ser45 China 
Guichard et 
al.[42] 8/24(33.3) 4/35(11.4) 30/80(37.5) 
Missense 
Insertion 
Deletion 
Asp32, Ser33, Ser37, 
Thr41,Thr42 Ser45 France 
Li et al.[44] 14/45(31.1) 6/52(11.5) 9/44(20.5) 
Missense 
Deletion 
Asp32, Ser33,Gly34, 
His36, Ser37, Thr41, 
Ser45 ,Asn387 
USA, Netherlands, 
China 
Bengochea et 
al.[46] 8/20(40) 3/18(16.7) 5/24(20.8) 
Missense 
Insertion 
Asp32, Ser33, Ser37, 
Thr41 Ser45 Thailand, France 
Kim et al.[48] 0/4(0) 0/21(0) 1/14(7.1) Missense Ser33 China 
Park et al.[52] 0/6(0) 13/78(16.7) NA 
Missense 
Deletion 
Asp32, Ser33,Gly34 
Ile35, His36, Ser37, 
Thr41, Ser45 Korea 
Edamoto et 
al.[55] 16/51(31.4) 5/26(19.2) 3/23(13) Missense 
Asp32, Ser33, His36, 
Ser37, Thr41, Ser45 Japan, Switzerland 
Wong et 
al.[57] 0/2(0) 5/48(10.4) 2/10(20) 
Missense 
Deletion 
Asp32, Ser33,Gly34 
Ile35, Ser37, Thr41, 
Ser45 China 
Hsu et al.[62] 23/92(25) 30/323(9.3) 4/19(21.1) 
Missense 
Deletion 
Asp32, Gly34, 
Thr41, Ser45 Taiwan 
Huang et 
al.[64] 9/22(41) NA NA Missense 
Asp32, Ser33,Ser37, 
Thr41, Ser45 Japan, Switzerland 
Legoix et 
al.[65] 7/30(23.3) 5/26(19.2) 13/64(20.3) 
Missense 
Deletion 
Asp32, Ser33,Gly34, 
Ser37, Thr41, Ser45 France 
Terris et 
al.[66] 2/7(28.6) 3/14(21.4) 9/52(17.3) 
Missense 
Deletion 
Asp32, Ser33,Gly34, 
Ser37, Ser45 France 
Kondo et 
al.[67] 7/22(31.8) 1/8(12.5) 1/9(11.1) 
Missense 
Deletion 
Asp32, Ser33,Gly34 
Ile35, His36, Ser37, 
Thr41, Ser45 Japan 
Total 118/442(26.7) 103/885(11.6) 91/432(21.1)    
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Figure 1. Summary of CTNNB1 exon 3 mutations in HCV-related HCC. Illustrated are the locations of the CTNNB1 
mutations reported in 68 tumors from 65 HCC patients (one tumor with p.D32_G48del, not shown). N-terminal 
serine and threonine phosphorylation residues are indicated bold. Numbers in brackets are absolute number of 
tumors tested with given mutation. 
HCV structural proteins activate Wnt/β-catenin signaling 
The HCV genome is a single-stranded positive sense 9.6kb RNA molecule, which includes a 
single open reading frame encoding a polyprotein of ≈ 3,000 amino acids that following 
translation is cleaved into 10 mature proteins by both host and viral proteases. These proteins 
are the structural proteins (core, E1 and E2), the viroporin p7 and the non-structural proteins 
(NS2, NS3, NS4A, NS4B, NS5A and NS5B). The pro-oncogenic pathogenesis of HCV appears 
mainly mediated by the core protein and two of the non-structural proteins NS3 and NS5A 
[79]. These pro-oncogenic effects appear to depend largely on the potential of these proteins 
to mediate activation of Wnt/β-catenin signaling. 
Core protein 
The 21kDa core protein is the major component of HCV. Despite lacking obvious organelle 
localization signals in the primary sequence, it is not only detected in the cytosol, but also in 
th Golgi apparatus, in lipid droplets and in the nucleus [80, 81]. Remarkably, in the latter 
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organelle it serves as a regulator of hepatocyte transcription, facilitating Wnt/β-catenin 
signaling. This is brought about by upregulation of canonical Wnts, FZD and LRP5/6 receptors 
[82, 83] while concomitantly inhibiting transcription of Wnt antagonists SFRP2 and DKK1 [84]. 
The latter effect is mediated by epigenetic silencing of the promoters involved by core protein-
mediated recruitment of DNA methyltransferase-1 (DNMT1) and histone deacetylase-1 
(HDAC1) to the transcription start site, an effect already detected early in hepatitis infection 
[84, 85]. In addition, the HCV core protein mediates hypermethylation of the CDH1 (E-cadherin) 
gene promoter [86]. Reduced production of E-cadherin results in diminished sequestering of 
β-catenin in β-catenin/E-caherin complexes and thus enhanced activation of Wnt/β-catenin 
signaling (Fig.2). Hence, the core protein mediates a plethora of molecular events leading to 
increased Wnt/β-catenin signaling and thus apparently HCV is under substantial selection 
pressure to provoke Wnt/β-catenin signaling. Potential sources for this selection pressure are 
a necessity to counteract hepatocyte apoptosis, whereas Wnt/β-catenin signaling-driven 
expansion of the HCV-infected compartment may be involved as well. 
NS5A 
The notion that HCV is under selection pressure to counteract apoptosis is further reinforced 
by observations that NS5A not only functions as a component of the HCV RNA replication 
complex [87], but also binds to the p85 regulatory subunit of phosphoinositide 3 kinase (PI3K) 
thus activating the downstream effector serine/threonine kinase Akt [88, 89]. Akt activation 
provides powerful anti-apoptotic signal and also mediates the inactivation of GSK3β, 
stabilization of β-catenin and subsequent stimulation of β-catenin dependent transcription 
[90]. In addition, the NS5A protein binds and stabilizes β-catenin directly [91], apparently 
independent of its effects on Akt and GSK3β [92] (Fig.2). Thus the multiple stimulatory effects 
of NS5A on Wnt/β-catenin signaling are also testimony of the selection pressure of HCV to 
increase hepatocyte Wnt/β-catenin signaling. 
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Figure 2. Wnt/β-catenin signaling is activated by HCV virus proteins. HCV core protein elevates gene expression 
of Wnt ligands, FZD and LRP5/6 receptors but decreases the expression of Wnt antagonists DKK and SFRP by 
recruiting DNMT1 and HDAC1 to their transcription start sites. In addition, HCV core protein releases β-catenin 
from the β-catenin/E-cadherin complexes by suppression of the CDH1 gene promoter encoding E-cadherin. NS5A 
protein activates PI3K/Akt signaling leading to the inactivation of GSK3β and subsequent reduced breakdown of 
β-catenin, or directly stabilizes β-catenin protein. The overall effect is the cytoplasmic accumulation of β-catenin 
and stimulation of downstream transcription. 
More Wnt/β-catenin signaling-stimulating effects 
The hypotheses that successful HCV-infection critically depends on its potential to stimulate 
Wnt/β-catenin signaling is further supported by observations that, in addition to direct 
activation, HCV infection leads to elevation of microRNA-155 (miR-155) [93] and microRNA-
199a-5p [94], in turn triggering Wnt/β-catenin signaling. MiR-155 acts as an oncomiR by 
targeting the suppressor of the cytokine signaling 1 (SOCS1) gene [95] that directly inhibits 
APC expression, one of the major negative regulators of Wnt/β-catenin signaling [93]. 
Moreover, both direct and indirect activation by HCV viral proteins may explain the notable 
dysregulation of Wnt/β-catenin signaling in hepatitis C and related HCC subclass. Moreover, 
HCV core, NS3 and NS5A proteins may facilitate further oncogenic transformation of infected 
hepatocytes [79] by suppression of DNA repair mechanisms, potentially causing CTNNB1 
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mutations. Support for this idea could be found in the observation that in experimental 
animals hepatocarcinogenic nitrosamine diethylnitrosamine (DEN) provokes cancer by 
inducing CTNNB1 mutations [96, 97] and thus increased mutagenic pressure through 
corrupting DNA repair may be preferentially associated with this mutation. Hence effects on 
the DNA repair machinery exerted by HCV core, NS3 and NS5A may link increased Wnt/β-
catenin signaling mediated by direct effects of these proteins early in infection to mutation-
mediated activation of Wnt/β-catenin signaling later in the progression to HCC. 
Wnt/β-catenin signaling paves the way for chronic hepatitis C to HCC 
Inflammation 
The HCV virus battles with the immune system. Thus negative modulation of inflammatory 
responses through enhanced Wnt/β-catenin signaling could conceivably provide further 
selection pressure of HCV to acquire Wnt/β-catenin signaling-activating properties. The effect 
of Wnt/β-catenin signaling, however, on hepatocyte immune responses remains controversial. 
On one hand, Wnt/β-catenin signaling could suppress the immune response by blunting T cell 
activation [98, 99], reducing TNF release [100] or stimulating the production of the 
chemokine-like chemotactic factor leukocyte cell-derived chemotaxin 2 (LECT2) and invariant 
NKT cells (iNKT) responses, both of which relay antiinflammatory response [101]. On the other 
hand, Wnt/β-catenin signaling triggers inflammatory responses by activating the pro-
inflammatory NF-κB pathway, as evident from experimentation in a hepatocyte-specific APC 
and LECT2 knockout (APC–/–LECT2–/–) mouse model [101]. In potential agreement, germline 
genetic variations in Wnt/β-catenin signaling elements were significantly associated with the 
risk for inflammation in HCV-infected males [102]. Thus the issue as to how HCV-elicited 
Wnt/β-catenin signaling relates to HCV-provoked inflammation warrants further 
experimentation. 
Fibrosis to cirrhosis and HCC development 
Chronic inflammation evoked by HCV infection may culminate in liver fibrosis. Such fibrosis 
progresses gradually and disrupts liver physical structure and function over the course of 
several decades, finally resulting in fatal diseases such as cirrhosis and HCC [103]. Given HCV-
stimulation of Wnt/β-catenin signaling probably evolved to support the early phases of viral 
infection, emerging data suggest that activated Wnt/β-catenin signaling by HCV participates 
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in the pathogenesis of liver fibrosis as well [102, 103], mainly by enhancing hepatic stellate 
cell (HSC) activation and survival [104]. The subsequent progression toward full-blown HCC is 
a complex process involving many various signaling pathways, but especially crosstalk 
between epidermal growth factor receptor (EGFR) signaling  and fibroblast growth factor (FGF) 
receptor signaling and aberrant activation of Wnt/β-catenin signaling appears important here. 
The EGFR pathway controls a variety of signals ranging from cell proliferation, cell 
motility, apoptosis decrease, to epithelial mesenchymal transition, upregulation of matrix 
metalloproteinases (MMP), and even stem cell maintenance [105]. EGFR is highly expressed 
in the adult liver [106] and plays an essential role in the G1/S phase transition for hepatocyte 
proliferation [107]. EGFR pathway dysregulation has been reported in 60% to 80% of HCC 
patients [108], and associated with the late stages and the degree of tumor differentiation 
[109, 110]. EGFR favors HCV entry through co-internalization of a HCV-CD81-EGFR complex 
following binding of EGFR ligands to the receptor and subsequent endocytosis [111, 112]. 
Following clathrin-mediated endocytosis of the EGFR, the receptor is routed for eventual 
intracellular degradation [113]. The viral NS5A protein, however, perturbs EGFR trafficking 
and degradation, increasing EGFR signaling and contributing to HCV-mediated HCC 
development [114]. Binding of Wnt1 and Wnt5a to FZD transactivates EGFR signaling by MMP-
mediated release of soluble EGFR ligands, such as TGFα [115]. Activated β-catenin might form 
heterodimers with EGFR to enhance EGFR pathway activation [116]. Conversely, EGFR 
signaling contributes to Wnt/β-catenin signaling in various ways. Firstly, EGFR can directly 
induce tyrosine phosphorylation of β-catenin at residue Y654, thereby decreasing the binding 
with cell-adhesion complexes and releasing it for nuclear signaling [104, 117]. In fact, this 
phenomenon has been observed for a large number of growth factors signaling through 
receptor tyrosine kinases, such as HGF and FGFs that are produced in excess by the cirrhotic 
tissue adjacent to tumor tissue [28, 118-120]. Secondly, EGFR stimulates the PI3K/Akt and 
Ras/Raf/MEK/ERK cascades that both can promote β-catenin signaling through inhibiting 
GSK3β activity [121-125] (Fig.3). Thus HCV-mediated activation of Wnt/β-catenin signaling 
may initiate a vicious interaction between EGFR and Wnt signaling, promoting potentially pro-
oncogenic hepatocyte proliferation. 
Similar to the EGFR pathway, FGF-initiated signaling is a cardinal regulator of hepatocyte 
proliferation, differentiation, embryonic development and organogenesis as well as hepatic 
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tumorigenesis [126, 127]. Especially in chronic hepatitis C-associated HCC, activation of FGF 
signaling is observed [128, 129] and increased FGF levels are associated with enhanced HCV 
replication and release of infectious particles [130]. Crosstalk of Wnt and FGF pathways in 
HCV-related HCC is supported by observations that FGF signaling leads to the release of β-
catenin from the β-catenin/E-cadherin complexes due to the phosphorylation of Tyr654 as 
described above. Furthermore, FGF2 increases expression of β-catenin mRNA, upregulates β-
catenin nuclear translocation and inactivates GSK3β [131], probably mediated through 
activation of PI3K/Akt and Ras/Raf/MEK/ERK pathways. Conversely, Wnt/β-catenin signaling 
is able to activate FGF signaling by increasing FGF18 and FGF20 expression [132] (Fig.3). Thus 
again, vicious interaction between Wnt/β-catenin signaling and FGF signaling appears to occur. 
Of interest, it has been reported that the Src homology region 2 domain-containing 
phosphatase-2 (SHP-2) can be activated by HCV structural E2 protein [133]. Thus conceivably 
SHP-2 may be an effector on EGFR and FGF signaling in HCV related HCC. Overexpression of 
SHP-2 promotes liver tumor cell growth and metastasis by coordinately activating not only 
PI3K/Akt and Ras/Raf/MEK/ERK pathways [121] but also Wnt/β-catenin signaling [134]. The 
latter effect is due to tyrosine dephosphorylation of parafibromin/Cdc73, acting as a tumor 
suppressor inhibiting CYCLIND1 and C-MYC, together with SUV39H1. As a result, parafibromin 
acquires the ability to bind β-catenin stably, overriding the repression effect and inducing the 
expression of Wnt target genes [134] (Fig.3). Together, these results suggest that SHP-2 is one 
of the critical molecules enhanced during early HCV infection and contributes to the later 
progression to final HCC, which needs further investigation. 
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Figure 3. Crosstalk of Wnt/β-catenin pathway with EGFR and FGF pathways in HCV related HCC. HCV promotes 
Wnt signaling as well as EGFR and FGF pathways. The Wnt/β-catenin and EGFR pathways activate each other. 
Binding of Wnt ligands with FZD receptors transactivates EGFR signaling by MMP-mediated release of soluble 
EGFR ligands. EGFR signaling transactivates Wnt/β-catenin signaling through PI3K/Akt and Ras/Raf/MEK/Erk 
pathways but also by releasing β-catenin from β-catenin/E-cadherin complexes due to residue Tyr654 
phosphorylation. Activated β-catenin forms heterodimers with EGFR and in turn promote EGFR pathway. On the 
other hand, Wnt signaling stimulates FGF signaling by inducing FGF18 and FGF20 ligand expression. In turn, the 
association of FGF19 to FGFR leads to the release of β-catenin from the β-catenin/E-cadherin complexes. FGF2 
signaling inhibits GSK3β activity through PI3K/Akt and Ras/Raf/MEK/Erk pathways. Activated SHP-2 in both 
PI3K/Akt and Ras/Raf/MEK/Erk pathways dephosphorylates parafibromin which acquires the ability to bind β-
catenin stably, overriding the repression effect on the CYCLIND1 and C-MYC expression and triggering 
downstream signaling. 
Conclusion 
As one of the important cascades involved in HCV-related HCC initiation and development, 
Wnt/β-catenin signaling is aberrantly activated by HCV viral core and NS5A proteins. In turn, 
stimulated Wnt/β-catenin signaling promotes progression of hepatitis C during inflammation 
and fibrosis eventually promoting cirrhosis and HCC. This interaction is further aggravated by 
a vicious circle involving the EGFR and FGF pathways.  
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Abstract 
Aberrant activation of Wnt/β-catenin signaling plays a key role in the onset and development 
of hepatocellular carcinomas (HCC), with about half of them acquiring mutations in either 
CTNNB1 or AXIN1. However, it remains unclear whether these mutations impose sufficient β-
catenin signaling or require upstream Wnt ligand activation for sustaining optimal growth, as 
previously suggested for colorectal cancers. Using a panel of nine HCC cell lines we show that 
siRNA mediated knock-down of β-catenin impairs growth of all these lines. Blocking Wnt 
secretion, either by treatment with the IWP12 porcupine inhibitor or knockdown of WLS, 
reduces growth of most of the lines. Unexpectedly, interfering with Wnt secretion does not 
clearly affect the level of β-catenin signaling in the majority of lines, suggesting that other 
mechanisms underlie the growth suppressive effect. However, IWP12 treatment did not 
induce autophagy or endoplasmic reticulum (ER) stress, which may have resulted from the 
accumulation of Wnt ligands within the ER. Similar results were observed for colorectal cancer 
cell lines used for comparison in various assays. These results suggest that most colorectal and 
liver cancers with mutations in components of the β-catenin degradation complex do not 
strongly rely on extracellular Wnt ligand exposure to support optimal growth. In addition, our 
results also suggest that blocking Wnt secretion may aid in tumor suppression through 
alternative routes currently unappreciated. 
Keywords: Hepatocellular carcinoma; Wnt/β-catenin signaling 
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Introduction 
Hepatocellular carcinoma (HCC) is considered as the fifth most common cancer and the third 
main reason for cancer related death with 748,000 cases and 695,000 deaths each year [1, 2]. 
The etiology of HCC includes Hepatitis B virus (HBV) or Hepatitis C virus (HCV) infection, alcohol 
liver disease, non-alcoholic steatohepatitis (NASH) and aflatoxin-B1 exposure [3]. More than 
80% of all HCCs occur in Eastern and Southeastern Asia where the main cause is HBV combined 
with exposure to aflatoxin-B1 [4]. In Europe, Japan and the United States, HCV represents the 
dominant risk factor, together with alcohol abuse and nonalcoholic fatty liver diseases [5, 6]. 
Wnt/β-catenin signaling plays an important role in a wide range of biological processes, 
involving embryonic patterning, cell proliferation, differentiation, angiogenesis, 
carcinogenesis, metastasis and drug resistance [7-9]. Underscoring the relevance of this 
pathway, many tumor types including HCC, exhibit enhanced Wnt/β-catenin signaling that 
strongly contributes to tumor growth [10]. Activation of Wnt/β-catenin signaling starts with 
the secretion of Wnt ligands. Wnts produced within the endoplasmic reticulum (ER) are 
palmitoylated by the Wnt acyl-transferase porcupine (PORCN), which is essential for their 
secretion and signaling activity. Following this lipid modification, Wntless (WLS) is needed to 
shuttle the Wnt proteins from the Golgi to the plasma membrane where they can signal in an 
autocrine or paracrine manner [11]. In the absence of upstream Wnt signaling, β-catenin is 
phosphorylated at N-terminal Ser/Thr residues by a multiprotein complex consisting of the 
adenomatous polyposis coli (APC) tumor suppressor, scaffold proteins AXIN1, AXIN2 and 
AMER1, and the kinases GSK3 and CK1α. Phosphorylated β-catenin is then ubiquitinated, 
leading to its proteasomal degradation [12-14]. The overall effect is low β-catenin levels in the 
cytoplasm and nucleus of unstimulated cells.Upon binding of Wnt ligands to Frizzled and 
LRP5/6 co-receptors, Disheveled (DVL) becomes phosphorylated, subsequently resulting in 
the inhibition of the β-catenin destruction complex [15]. As a result, β-catenin is stabilized and 
is able to translocate to the nucleus and associate with members of the TCF/LEF family of 
transcription factors, thus regulating the expression of specific downstream Wnt/β-catenin 
target genes thereby affecting cellular decisions [4]. In addition to this classical (canonical) 
Wnt signaling pathway, Wnts can also signal in an alternative (non-canonical) fashion 
independent of β-catenin through associating with Frizzled and ROR1/2 receptors instead of 
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LRP5/6. Activation of non-canonical Wnt signaling mainly affects cellular processes involved 
in migration and cellular polarity [8]. 
Hepatocarcinogenesis is a multistep process, progressing from a normal hepatocyte to 
a transformed phenotype as a result of the accumulation of aberrant genetic and epigenetic 
modifications and activation of various signaling pathways [16-18]. Increasing evidence 
indicates that activation of Wnt/β-catenin signaling is critical in hepatic oncogenesis [19, 20]. 
About 40%-70% of HCCs are characterized by nuclear accumulation of β-catenin, the hallmark 
of active signaling. Various molecular and genetic alterations contribute to aberrant activation 
of Wnt/β-catenin signaling. Mutations within components of the canonical Wnt/β-catenin 
signaling enhance stabilization of β-catenin and transcriptional activity in the nucleus. 
Approximately one third of all HCCs carry oncogenic β-catenin mutations within exon 3 at the 
N-terminal phosphorylation residues, making the protein more resistant to proteolytic 
degradation [21]. In another subset of tumors, loss-of-function mutations of negative 
regulators are observed in the APC and AXIN1 genes, respectively in 1-3% and 8-15% of tumors 
[19], both causing compromised ability to degrade β-catenin [8]. In addition to mutations, 
various other mechanisms have been suggested to promote β-catenin signaling, including 
overexpression of Wnt ligands and/or their corresponding receptors, and reduced expression 
of extracellular inhibitors [22]. Given the importance of β-catenin signaling for hepatic 
oncogenesis, various treatments targeting this route have been evaluated [23]. 
Cancers harboring mutations within intracellular components of the β-catenin signaling 
pathway, i.e., mutation of APC, AXIN or β-catenin itself, were often considered to become 
largely independent of upstream regulation by extracellular Wnt ligands. This belief has 
however been challenged during the last years. For example, Wnt antagonists SFRPs and DKKs 
are reported to attenuate Wnt signaling in colorectal cancer (CRC) [24, 25]. Recently, it was 
demonstrated that interfering with Wnt secretion or reducing the expression of specific Wnt 
ligands impaired the growth of APC and β-catenin mutant CRC cell lines [26]. These results 
also indicated that interfering with Wnt secretion, for example using the newly developed 
PORCN inhibitors [27, 28], could be useful as an additive treatment option for tumors 
characterized by enhanced β-catenin signaling. Here, we have investigated whether this also 
holds truth for β-catenin or AXIN1 mutant liver cancer cells. 
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Materials and methods 
Cell lines 
Human HCC cell lines Hep3B, Huh6, Huh7, PLC/PRF/5, SNU182, SNU398, SNU449 and CRC cell 
lines CACO2, DLD1, HT29, SW480, HCT116, LS174T, SW48 and RKO were cultured in 
Dulbecco’s modified Eagle medium (DMEM) (Invitrogen-Gibco, Breda, The Netherlands) 
complemented with 10% (v/v) fetal calf serum (Hyclone, Lonan, Utah), 100 IU/ml penicillin, 
100 μg/ml streptomycin and 2 mM L-glutamine (Invitrogen-Gibco). The hepatoblastoma cell 
line HepG2 was cultured on fibronectin/collagen/albumin-coated plates (AthenaES) in 
Williams E medium (Invitrogen-Gibco, Breda, The Netherlands) complemented with 10% (v/v) 
fetal calf serum, 100 IU/ml penicillin, 100 μg/ml streptomycin and 2 mM L-glutamine. HepaRG 
was cultured in William’s E medium supplemented with 10% (v/v) fetal calf serum, 100 IU/ml 
penicillin, 100 µg/ml streptomycin, 5 µg/ml insulin (Sigma-Aldrich, St Louis, MO), and 50 µM 
hydrocortisone hemisuccinate (Sigma-Aldrich, St Louis, MO). Identity of all cell lines was 
confirmed by STR genotyping. CTNNB1 mutation status was confirmed in all the nine HCC cell 
lines by Sanger sequencing and was consistent with those reported at COSMIC, the Catalogue 
Of Somatic Mutations In Cancer (http://cancer.sanger.ac.uk) [29]. 
For the preparation of conditioned medium, L-Control and L-Wnt3A cells were cultured 
in complete DMEM medium, followed by collection and filtration of medium according to 
standard procedures. HCC and CRC cell lines were stimulated with 25% L-Control or L-Wnt3A 
medium. 
Reagents 
IWP12 (Sigma-Aldrich, St Louis, MO) was dissolved in dimethyl sulfoxide (DMSO) (Sigma-
Aldrich, St Louis, MO) with a final stock concentration of 10mM. Antibodies specific for β-
catenin (Cat. #9561, Cell Signaling Technology), dishevelled adaptor protein (DVL2) (Cat. 
#3216, Cell Signaling Technology), WLS (Cat.#MABS87, clone YJ5 Millipore), LC3Ⅰ/Ⅱ (Cat. 
#4108, Cell Signaling Technology), GPR177(Wls/Evi) (Cat.#MABS87, Millipore) and β-actin (sc-
47778, Santa Cruz), Tubulin (sc-8035, Santa Cruz) anti-rabbit or anti-mouse IRDye-conjugated 
secondary antibodies (Stressgen, Glandford Ave, Victoria, BC, Canada) were used for western 
blot analysis. 
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Table1. Gene mutations of Wnt/β-catenin signaling components in HCC and CRC cell lines 
Cell line Gene AA alteration Zygosity 
HCC 
HepG2 CTNNB1 p.W25_I140 del Heterozygous 
Huh6 CTNNB1 p.G34V Heterozygous 
SNU398 CTNNB1 p.S37C Heterozygous 
Hep3B AXIN1 p.R146* Homozygous 
PLC/PRF/5 AXIN1 p.(R373_M418 del) Homozygous 
SNU449 AXIN1 p.R712* Homozygous 
Huh7    
HepaRG    
SNU182    
CRC 
SW480 APC p.Q1338* Homozygous 
HT29 APC p.T1556fs*3 Heterozygous 
  p.E853* Heterozygous 
Caco2 APC p.Q1367* Homozygous 
DLD1 APC p.R2166* Heterozygous 
  p.I1417fs*2 Heterozygous 
 AXIN1 p.L396M Heterozygous 
 RNF43 p.G659fs*41 Heterozygous 
SW48 CTNNB1 p.S33Y Heterozygous 
 RNF43 p.G659fs*41 Heterozygous 
  p.V299fs*143 Heterozygous 
HCT116 CTNNB1 p.S45del Heterozygous 
 RNF43 p.R117fs*41 Heterozygous 
LS174T CTNNB1 p.S45F Homozygous 
RKO RNF43 p.G659fs*41 Heterozygous 
Gene knockdown by small interfering RNA (siRNA) 
Smartpool ON-TARGETplus siRNAs targeting CTNNB1 and WLS were obtained from 
Dharmacon. The ON-TARGETplus Non-targeting siRNA #2 was used as negative control. Cells 
were reverse-transfected in a 96-well plate using a total of 0.2 ul DharmaFECT formulation 4 
(Thermo Fischer Scientific) and 25nM of each siRNA per well. Following 72 hours incubation, 
the effect on knock-down was determined by western blotting. 
Quantitative real-time polymerase chain reaction 
RNA was isolated with a Machery-NucleoSpin RNA II kit (Bioke, Leiden, The Netherlands) and 
quantified using a Nanodrop ND-1000 (Wilmington, DE, USA). CDNA was prepared from total 
RNA using a cDNA Synthesis Kit (TAKARA BIO INC) and subjected to quantitative Real-Time 
PCR analyses. Analyses were performed using the StepOne Real-Time PCR System and the 
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StepOnev2.0 software (Applied Biosystem, Darmstadt, Germany). Primer sequences are 
provided in supplementary Table1. All expression levels are depicted relative to the expression 
of GAPDH. 
Western blot assay 
Cells were lysed in Laemmli sample buffer with 0.1 M DTT and heated for 5-10 minutes at 
95 ℃, followed by loading and separation on a 8-15% sodium dodecyl sulphate-
polyacrylamide gels (SDS-PAGE). After 90 min running at 120 V, proteins were 
electrophoretically transferred onto a polyvinylidene difluoride (PVDF) membrane (Invitrogen) 
for 1.5 h with an electric current of 250 mA. Subsequently, the membrane was blocked with 
2.5 ml Odyssey Blocking Buffer and 2.5 ml PBS containing 0.05% Tween 20 (PBS-T), followed 
by incubation with primary antibody (all 1:1000) overnight at 4 °C. The membrane was washed 
3 times with PBS-T followed by incubation for 1.5 h with anti-rabbit or anti-mouse IRDye-
conjugated secondary antibodies (LI-COR Biosciences, Lincoln, USA) (1:5000) at room 
temperature. Blots were assayed for β-actin or Tubulin content as standardization of sample 
loading, scanned, and quantified by Odyssey infrared imaging (Li-COR Biosciences, Lincoln, NE, 
USA). Results were visualized and quantified with Odyssey 3.0 software. 
β-catenin reporter assays 
The β-catenin reporter assays were basically performed as previously described [30, 31]. In 
short, twenty hours before transfection, we plated 105 cells per well on 12-well plates. Each 
well was transfected with 500 ng Wnt Responsive Element (WRE) or Mutant Responsive 
Element (MRE) vectors and 20 ng TK-Renilla using polyethylenimine (PEI) (Sigma-Aldrich, St 
Louis, MO) or Fugene HD (Promega). We measured luciferase activities in a LumiStar Optima 
luminescence counter (BMG LabTech, Offenburg, Germany) and normalized the data for the 
transfection efficiency by using the Dual Luciferase Reporter Assay system (Promega) 
according to the manufacturer’s instruction. Transfections were performed in triplicate and 
the mean and standard error were calculated for each condition. The β-catenin reporter 
activities are shown as WRE/MRE ratios. 
MTT assay 
10 mM 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) (Sigma) was 
added to cells seeded in 96-well plates and incubated at 37°C with 5% CO2 for 3 h. The medium 
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was removed and 100 µl DMSO was added to each well. The absorbance of each well was read 
on a microplate absorbance reader (BIO-RAD) at wavelength of 490 nm. For siRNA mediated 
knockdown of genes, 4 independent wells were assayed for each cell line at least two times, 
whereas for IWP12 treatment 6 independent wells were used. The mean and standard error 
were calculated for each condition. 
Cell cycle analysis 
Around 60%-80% confluency, cells were trypsinized and washed with PBS and then fixed in 
cold 70% ethanol overnight at 4℃. The cells were washed twice with PBS and incubated with 
20ug/ml RNase at 37°C for 30 min followed by incubation with 50ug/ml Propidium Iodide (PI) 
at 4°C for 30min. Then samples were tested immediately by FACS. Cell cycle was analyzed by 
FlowJo_V10 software. For each treatment, two independent wells were tested for Huh6, 
SNU449 and Huh7 two times. The mean and standard error were calculated for each condition. 
Statistical analysis 
All results were presented as mean ± SD. Comparisons between groups were performed with 
one sample t test. Differences were considered significant at a p value less than 0.05. 
Results 
β-catenin signaling activity of HCC cell lines 
To investigate the importance of β-catenin signaling and Wnt secretion for sustaining cell 
growth, we employed 9 HCC cell lines, listed in Table 1 in which gene mutations related to 
Wnt/β-catenin signaling are depicted. We also used 8 CRC cell lines for comparison in various 
assays, known to largely depend on β-catenin signaling for their growth. First, we determined 
the baseline β-catenin signaling activity for all these cell lines using a β-catenin reporter assay 
and qRT-PCR of AXIN2, a well-established β-catenin target gene. As indicated in Figure 1, in 
line with previous publications, all β-catenin mutant HCC lines (SNU398, HepG2 and Huh6) 
showed a robust induction of both reporter activity as well as high AXIN2 expression. The 
AXIN1 mutant lines (PLC/PRF/5, Hep3B and SNU449) also displayed enhanced reporter activity, 
albeit generally more modest, whereas the expression of AXIN2 was low. Interestingly, among 
the HCC lines without an obvious mutation, SNU182 presented with high β-catenin signaling 
activity, both on reporter level and AXIN2 expression. Huh7 and HepaRG showed low reporter 
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activity together with low AXIN2 expression. All CRC lines, except RKO being wild type for APC 
and CTNNB1, showed the expected increase in reporter activity (Figure S1). 
 
Fig.1. Baseline β-catenin signaling activity in HCC cell lines. (A) β-catenin luciferase reporter assay showing β-
catenin signaling activity in HCC cell lines (mean ± SD, n = 3). The β-catenin reporter activities are depicted as 
WRE/MRE ratios. (B) QRT-PCR assay showing expression of the β-catenin target gene AXIN2 in HCC cell lines 
(mean ± SD, n = 3). Expression levels are depicted relative to the housekeeping gene GAPDH. 
Requirement for β-catenin signaling to sustain efficient cell growth 
Next, we determined the dependence on β-catenin signaling for supporting efficient growth 
by transiently transfecting smartpool siRNAs targeting CTNNB1 or a control siRNA, followed 
by a MTT assay to test cell numbers after 3 days of culture. For most cell lines we accomplished 
more than 80% knock-down of β-catenin at protein level as determined by quantitative 
western blot analysis, with the exception of HepaRG in which a 65% reduction was observed 
(see Figures 2A and S2). As indicated in Figure 2B, β-catenin signaling activity was clearly 
suppressed by siRNA mediated knockdown in the three lines tested for this purpose, i.e. Huh6, 
SNU449 and Huh7. All HCC cell lines were inhibited significantly in their growth (Figure 2C) 
suggesting that β-catenin signaling is important for the growth of these tumor cells, even in 
the ones that show only low to modest levels of signaling, such as Huh7 and HepaRG. Cell cycle 
analysis in three lines showed that β-catenin knockdown provoked a dramatic G0/G1 phase 
arrest in Huh6 (Fig 2D). Also in Huh7 a notable increase of cells in G0/G1 is observed with a 
significant reduction of cells in the G2/M phase, whereas for SNU449 a trend is observed 
towards more cells in G0/G1 and less cells in S-phase. As expected, all five tested CRC cell lines 
showed a significantly reduced growth upon β-catenin knockdown (Figure 2E). 
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Expression levels of WNT ligands in HCC cell lines 
Taken together, the results above indicate that targeting the β-catenin signaling pathway 
represents an attractive route to suppress the growth of HCCs. This pathway has however 
been refractory to target in an efficient manner. More recently, inhibitors of Wnt secretion 
have been proposed as treatment options for malignancies dependent on Wnt-ligand 
secretion for their growth [26-28]. However, a prerequisite is that the tumor cells express 
sufficient levels of Wnt ligands capable of inducing β-catenin signaling. Hence, we investigated 
the expression profile of all 19 Wnt ligand genes in our HCC cell line panel by qRT-PCR. From 
the group of Wnt ligands more commonly associated with inducing β-catenin signaling (WNT1, 
2, 3, 3A, 8A, 8B, 10A and 10B), only WNT3 was clearly expressed in all HCC cell lines, followed 
by high WNT10A expression restricted to the SNU182 and HepaRG cell lines, and high WNT2 
expression in SNU449 (Figure 3A). The remaining ligands of this group are barely detectable 
or expressed at least at 10-fold lower levels in all cell lines (Figure S3). When piling up the 
expression of all Wnt ligands from this group (Figure 3B), the SNU182 cell line clearly stands 
out as one with overall highest expression level, which may explain its high β-catenin signaling 
activity reported above. The β-catenin and AXIN1 mutant cell lines are among the low-to-
intermediate ones. 
Among the group of Wnt ligands more commonly associated with activating alternative 
pathways (WNT4, 5A, 5B, 6, 7A, 7B and 11) depicted in Figure S4A, WNT5A was most 
prominently expressed, being very high in HepaRG and SNU182, and readily detectable in 
SNU398 and SNU449. The latter cell line also shows high expression of WNT5B and WNT7B. 
Other Wnt ligands of this group are detectable only at low levels or absent within 
Chapter 3 
56 
 
 
Fig.2. Requirement of β-catenin signaling for sustaining HCC cell growth. (A) HCC cell lines were transiently 
transfected with CTNNB1 siRNAs for 72 hours. Cell lysates were collected for western blotting with indicated 
antibodies. Tubulin and β-actin served as loading control (LC). (B) Silencing of β-catenin caused the reduction of 
β-catenin signaling activity (mean ± SD, n=2, two times). (C) Silencing of β-catenin inhibited the growth of HCC 
cell lines as determined by MTT assay (mean ± SD, n=4, two times). (D) Silencing of β-catenin alters cell cycle 
progression in Huh6 (all phases significantly changed) and Huh7 cells (G2/M phase significantly reduced). SNU449 
is less clearly altered, although the proportion of cells in S-phase is reduced (mean ± SD, n=2, two times). (E) β-
catenin knockdown reduced cell growth in colorectal cancer cell lines. Values depicted are relative to the ones 
obtained with the non-targeting siRNA that are arbitrarily set to 1. *p<0.05; **p<0.01. 
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most cell lines. Overall, SNU182 is again the most prominent expressing cell line, whereas the 
β-catenin and AXIN1 mutant cell lines are among the low-to-intermediate expressers (Figure 
3B). Of the remaining Wnt ligands (WNT2B, 9A, 9B and 16), WNT2B was highly expressed in 
PLC/PRF/5, SNU182, SNU398, and SNU449, while WNT9B was clearly expressed in Hep3B 
(Supplemental Figure S4B). 
Combining the expression of all Wnt ligands shows that SNU182 has again the highest 
overall levels, followed by HepaRG and SNU449 (Figure 3B, right panel). As all Wnt ligands 
trigger the phosphorylation of DVL2 upon binding of either the FZD_LRP5/6 or FZD_ROR1/2 
receptor complexes [32, 33], we determined baseline pDVL2 levels in all cell lines. As shown 
in Figure 3C, highest levels of phosphorylated DVL2 are observed in the three cell lines with 
highest Wnt levels, whereas for the remaining six lines no clear correlation can be observed. 
In summary, although all HCC cell lines show a large variation in Wnt ligand expression, they 
all express Wnt ligands that can contribute to β-catenin signaling. 
 
Fig.3. Expression levels of Wnt family members in HCC cell lines determined by qRT-PCR. (A) Expression levels of 
the top three expressed “canonical” Wnt ligands (mean ± SD, n=3). (B) Piled-up expression levels of canonical, 
non-canonical and overall Wnt ligands, respectively. All expression levels are depicted relative to the 
housekeeping gene GAPDH. (C) Baseline levels of phosphorylated DVL2 (pDVL2) in all HCC cell lines. Values below 
the image represent percentage of total DVL2 that is in the phosphorylated form (upper band). 
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Wnt secretion blockage reduces growth of HCC cells 
Given that most HCC cell lines show increased β-catenin signaling activity and expression of 
canonical Wnt ligands, we wished to investigate the consequences of suppressing the 
secretion of Wnt ligands. To this aim we used two methods, i.e., treatment with IWP12, an 
effective inhibitor of PORCN required for palmitoylation of Wnt proteins [34], and knockdown 
of WLS, which shuttles the palmitoylated Wnts from the Golgi to the plasma membrane. Both 
treatments are expected to reduce overall levels of secreted Wnt ligands. Following three days 
of IWP12 treatment, reduced cell numbers were observed for all β-catenin mutant cell lines 
(Figure 4A), ranging from 10% reduction (Huh6) to 35% (SNU398). Among the non-mutant 
lines, growth of HepaRG was strongly suppressed by IWP12, whereas Huh7 and SNU182 
showed more modest reductions of their growth. The AXIN1 mutant lines were not clearly 
affected by IWP12 with the exception of PLC/PRF/5. Effects on growth following knockdown 
of WLS were largely in line with IWP12 treatment, with the exception of the AXIN1 mutant 
lines Hep3B and SNU449 that were significantly suppressed by WLS knockdown, and a less 
impressive growth reduction of HepaRG when compared with IWP12 (Figure 4B). Examples of 
efficient WLS knockdown are shown in supplemental Figure S5. 
For comparison, the same assays were also performed on five CRC cell lines (Figure 4C,D). 
Both treatments showed the strongest growth suppression when applied to the β-catenin and 
RNF43 mutant HCT116 cell line. Intermediate effects were observed in DLD1, HT29, and 
SW480, whereas CACO2 was barely affected. In conclusion, most HCC and CRC cell lines are 
suppressed in their growth by both IWP12 treatment as well as WLS knockdown. 
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Fig.4. Inhibition of growth by Wnt secretion blockage. (A, C) IWP12 reduced cell growth of most HCC and CRC cell 
lines. Cell lines were incubated with 5 µM IWP12 for 72 hours and tested by MTT assay (mean ± SD, n=6, two 
times). Values depicted are relative to cell numbers obtained with the control DMSO treatment that are set to 1. 
(B, D) Cell lines were transiently transfected with WLS or non-targeting siRNAs for 72 hours, followed by MTT 
assay (mean ± SD, n = 4, two times). Values depicted are relative to cell numbers obtained with the non-targeting 
siRNA that are set to 1. *p<0.05; **p<0.01. 
Altered exposure to extracellular Wnt ligands does not affect β-catenin 
signaling activity in most HCC cell lines 
Previously, it was reported that Wnt secretion is required to maintain sufficiently high levels 
of canonical Wnt/β-catenin signaling activity in both APC and β-catenin mutant CRC cell lines 
[26]. Here, we asked whether the β-catenin and AXIN1 mutant HCC cell lines were also 
dependent on Wnt secretion to sustain this pathway activity. Exposure to extracellular Wnt 
ligands was again reduced by treating all cell lines with IWP12, after which we measured β-
catenin signaling activity using the reporter assay and AXIN2 qRT-PCR. After 48 hours, β-
catenin reporter activity was clearly suppressed only in SNU182 (Figure 5A), whereas the 
remaining eight HCC lines were not or only modestly inhibited in their reporter activity. 
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Reduction of AXIN2 expression confirmed the strong repressing effect of IWP12 in the SNU182 
cell line, while no reduction was observed in the other cell lines (Figure 5B). Overall, this 
analysis shows that IWP12 treatment barely affects β-catenin signaling activity in most HCC 
cell lines, with the exception of SNU182. 
In a true tumor setting, in addition to autocrine signaling, HCC cells are also exposed to 
Wnt ligands coming from the tumor microenvironment. Therefore, to determine the effects 
on β-catenin signaling of increased levels of extracellular Wnt ligands, we exposed them to L-
Wnt3A conditioned medium. As shown in Figure 5C, β-catenin reporter activity was strongly 
enhanced in the Huh7 cell line and clearly activated in SNU182, both of which were confirmed 
by qRT-PCR for AXIN2 (Figure 5D). Importantly, none of the β-catenin or AXIN1 mutant HCC 
lines showed enhanced β-catenin signaling following the addition of L-Wnt3A conditioned 
medium. 
These results indicate that β-catenin and AXIN1 mutant HCC cell lines appear largely 
insensitive to the level of Wnt ligand exposure for sustaining intracellular β-catenin signaling, 
which could either mean that the expressed mutant β-catenin or AXIN1 protein determine 
overall signaling levels in a dominant fashion or, alternatively, that these cells have defects in 
their machinery to transduce Wnt signals. To test the latter option, we determined pDVL2 
levels following treatment with IWP12 or L-Wnt3A conditioned medium (Figure 5E). 
Phosphorylation levels were not changed in Huh6, and only a modest reduction was observed 
in HepG2 following IWP12 treatment. In contrast, the SNU398 cell line showed a robust 
response in pDVL2 levels, decreasing from 21% to 7% by IWP12 treatment and upregulation 
to 59% following Wnt3A treatment. Thus, both options may hold true depending on the 
specific cell line under investigation. High variability in pDVL2 response was also observed in 
the remaining AXIN1-mutant and non-mutant HCC cell lines. The PLC/PRF/5 cell line showed 
a low baseline pDVL2 level, which was altered neither by IWP12 nor Wnt3A. The Huh7 and 
Hep3B cell lines also showed low baseline levels, which can however clearly be increased by 
the addition of Wnt3A. On the other hand, most DVL2 was phosphorylated at baseline in 
SNU182, which can be inhibited by IWP12, but can hardly be further stimulated by the addition 
of Wnt3A. Lastly, SNU449 and HepaRG showed intermediate pDVL2 levels at baseline that can 
both be reduced and activated by the respective treatments. Thus, all HCC cell lines show a 
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large variation in both their baseline levels of pDVL2 as well as responsiveness to Wnt ligand 
exposure, irrespective of their mutation status. 
 
Fig.5. Growth reduction due to decreased Wnt secretion appears independent from β-catenin signaling. (A) β-
catenin reporter activity was not clearly reduced by IWP12 in most HCC cell lines, except for SNU182 (mean ± SD, 
n=3). (B) QRT-PCR for AXIN2 showed that its expression following IWP12 treatment was only reduced significantly 
in the SNU182 cell line (mean ± SD, n=3, two times). (C) L-Wnt3A conditioned medium significantly promoted β-
catenin signaling activity in Huh7 and SNU182 cell lines. A significant albeit modest reduction of reporter activity 
was observed in HepG2. (mean ± SD, n=3). (D) Increased β-catenin signaling in SNU182 and Huh7 following L-
Wnt3A treatment was confirmed by AXIN2 qRT-PCR (mean ± SD, n=3, two times). All qRT-PCR and reporter values 
are depicted relative to the numbers obtained for the controls, which are arbitrarily set to 1. *p<0.05; **p<0.01. 
(E) Phosphorylation level of DVL2 protein following treatment with IWP12 or L-Wnt3A conditioned medium (“Con” 
is DMSO only, “L-Con” is L-Control conditioned medium). Values below the images represent percentage of total 
DVL2 that is in the phosphorylated form (upper band). 
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Response of CRC cell lines to alterations in Wnt ligand levels 
Among the eight CRC cell lines treated with IWP12, only HCT116 showed a significant 
reduction in β-catenin reporter activity as well as AXIN2 expression (Figure 6A,B). AXIN2 
expression was slightly reduced in HT29 and SW480, while CACO2 showed a reduced reporter 
activity only. Interestingly, HCT116 was also the only cell line in which both reporter activity 
and AXIN2 expression could be significantly stimulated by the addition of extracellular Wnt3A 
(Figure 6C,D). Analysis of pDVL2 levels in a selection of 5 CRC lines showed that overall baseline 
levels were low with the exception of HCT116 in which 60% of DVL2 is phosphorylated (Figure 
6E). IWP12 treatment shows the expected decrease in pDVL2 in HCT116, whereas none of the 
other cell lines showed clear alterations in pDVL2 levels following treatment with either IWP12 
or Wnt3A. 
 
Blocking Wnt Secretion Reduces Growth of HCC 
63 
 
 
Fig.6. Responsiveness of CRC cell lines to alterations in Wnt ligand levels. (A) β-catenin reporter activity was 
significantly reduced by IWP12 in CACO2 and HCT116 cell lines (mean ± SD, n=3). (B) QRT-PCR for AXIN2 showed 
that IWP12 treatment reduced its expression in HCT116. Modest but significant reductions were observed in 
HT29 and SW480 cell lines (mean ± SD, n=3, two times). (C) L-Wnt3A conditioned medium only increased β-
catenin reporter activity significantly in HCT116 (mean ± SD, n=3).(D) AXIN2 qRT-PCR confirmed upregulation of 
β-catenin signaling due to L-Wnta3A in HCT116. Significant but modest increases in AXIN2 expression are seen 
in SW48 and DLD1 (mean ± SD, n=3). Reporter values are depicted relative to the numbers obtained for the 
controls, which are arbitrarily set to 1. *p<0.05; **p<0.01. (E) Top image shows comparison of baseline pDVL2 
levels within a selection of five CRC cell lines. Bottom images show pDVL2 levels following treatment with IWP12 
or L-Wnt3A conditioned medium (“Con” is DMSO only, “L-Con” is L-Control conditioned medium). Values below 
the images represent percentage of total DVL2 that is in the phosphorylated form (upper band). 
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Blocking Wnt secretion does not lead to increased ER stress 
Blocking Wnt secretion using IWP12 or WLS knockdown reduces growth of HCC cell lines, 
apparently largely independent of β-catenin signaling. These treatments however also predict 
the accumulation of Wnt ligands in the ER, which may lead to activation of an ER stress 
response thereby reducing proliferation or inducing apoptosis. Therefore, ER stress was 
evaluated after IWP12 treatment in HCC cell lines using the expression of the ER-stress 
induced genes CHOP and GRP94 as a read-out. As shown in Figure 7A and 7B, expression of 
CHOP was clearly increased in SNU398 (4.5-fold), whereas GRP94 expression was elevated in 
SNU182 (2.8-fold). However, none of the other HCC cell lines displayed strong signs of 
induction. Overall, these results suggest that blocking Wnt secretion is not associated with the 
induction of a strong ER stress response. 
 
Fig.7. IWP12 treatment does not lead to the induction of a strong ER stress response or autophagy. Following 48 
hours of IWP12 treatment, the expression of the ER stress induced response genes CHOP (A) and GRP94 (B) was 
evaluated by qRT-PCR (mean ± SD, n=3). Except for a clear induction of CHOP in SNU398 and GRP94 in SNU182, 
IWP12 caused slight or no induction of an ER stress response in other cell lines. Values depicted are relative to 
those obtained for the untreated control samples that are arbitrarily set to 1. *p<0.05; **p<0.01. (C) Wnt 
secretion inhibition does not enhance autophagy in HCC cell lines. After incubation with IWP12 for 48 hours, the 
expression of LC3-Ⅱwas tested by western blot. 
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Wnt secretion inhibition does not induce autophagy 
Since knockdown of β-catenin or suppression of β-catenin signaling induced autophagy and 
even autophagic cell death in head and neck squamous cell carcinoma cells [35] and breast 
cancer stem-like cells [36], we further hypothesized that blocking Wnt secretion could exert 
similar effects on HCC cell lines. During autophagy the microtubule-associated protein 1A/1B-
light chain 3 (LC3) is converted through lipidation into a lower migrating isoform (LC3-II) 
detectable by western blot, which is used as an indicator of autophagosome formation. As 
indicated in Figure 7C, IWP12 treatment does not change the LC3 pattern in any of the HCC 
cell lines, showing that it does not induce autophagy. 
Discussion 
In this article we have investigated the importance of β-catenin signaling and Wnt secretion 
for sustaining hepatocellular carcinoma growth. Using a panel of 9 HCC cell lines we show that 
β-catenin signaling is required to support optimal growth in all of them, in line with other 
reports using a limited number of cell lines [37, 38]. This is to be expected for cell lines carrying 
oncogenic β-catenin mutations in which the activating mutation will have provided a selective 
growth advantage during tumor formation, but it also holds true for the non-mutant ones that 
show only low levels of baseline signaling, such as Huh7 and HepaRG, as well as the AXIN1 
mutant lines. The latter observation is of relevance as it has been debated whether AXIN1 
mutations lead to a significant enhancement of β-catenin signaling within liver cancers. This 
subset of tumors apparently lacks a robust nuclear β-catenin accumulation and shows no clear 
upregulation of target genes such as AXIN2 or GLUL [39, 40]. Also in our hands, the AXIN1 
mutant lines are among the lowest expressors of AXIN2. Nevertheless, in these lines AXIN2 
was readily detectable by qRT-PCR (Ct values below 28), in addition to β-catenin reporter 
activities approaching those of the β-catenin mutant ones. Given that also these lines are 
suppressed in their growth following β-catenin knockdown, it shows that the majority of HCCs 
independent of their mutational profile, rely on β-catenin signaling for optimal growth. 
Besides its role in signaling, β-catenin is also involved in cell-cell adhesion by directly 
binding to cadherins [41]. As such, the siRNA mediated knock-down that we apply here, will 
also likely reduce the amount of β-catenin sequestered at these adherens junctions. However, 
several investigations have shown that complete loss of β-catenin does not automatically lead 
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to alterations in cell adhesion, including hepatocytes and hepatocellular cancer cells [42-45]. 
In all cases, it was shown that ɣ-catenin compensates for its loss, thereby retaining normal cell 
adhesion. Importantly, these studies show that it is mainly the signaling function of β-catenin 
that is affected following knock-down. 
Next we addressed the question to what extent extracellular exposure to Wnt ligands 
contributes to the observed levels of β-catenin signaling. Using qRT-PCR we tested the 
expression of all 19 Wnt ligands in our cell line panel. The Wnt expression profile that we 
observed largely corresponds with the semi-quantitative analyses performed by others [22, 
46]. WNT3 is the most abundantly expressed “canonical” Wnt ligand uniformly expressed in 
all cell lines, whereas all the others are expressed at low level or only in a subset of the cell 
lines. SNU182 clearly stands out as the overall highest expressor of Wnt ligands, likely 
explaining the high level of phosphorylated DVL2 that we observed in this cell line [33]. Among 
the non-mutant lines, SNU182 also showed the highest β-catenin reporter activity and level 
of AXIN2 expression, comparable with the β-catenin mutant ones. As such, it is not 
unexpected that this cell line strongly relies on Wnt ligand secretion to retain increased β-
catenin signaling. In fact, it is the only HCC cell line that shows a clear reduction following Wnt 
secretion blockage on both reporter activity as well as AXIN2 expression level. On the other 
hand, the non-mutant Huh7 cell line expresses the lowest amount of Wnt ligands explaining 
its low baseline signaling levels, but it is highly responsive to Wnt ligand exposure for inducing 
strong β-catenin signaling. Within a true tumor setting it may represent a subtype of liver 
cancers that heavily depends on Wnt ligands expressed by cells within the tumor 
microenvironment, whose secretion would also be inhibited by the porcupine inhibitors 
employed here, whereas the SNU182 line is largely autonomous in this respect. Importantly, 
none of the β-catenin and AXIN1-mutant HCC cell lines are clearly affected in β-catenin 
signaling upon alterations in Wnt ligand exposure, irrespective of their source, suggesting that 
the expressed oncogenic β-catenin or mutant AXIN1 proteins determine overall signaling 
levels in a dominant fashion. 
In our hands this also holds true for most of the APC and β-catenin mutant CRC lines that 
we investigated. Among 8 CRC lines tested, only HCT116 shows a strongly reduced reporter 
activity and AXIN2 levels following IWP12 treatment, while it is also the only one in which both 
β-catenin signaling readouts are clearly increased after Wnt3A exposure. Analysis of pDVL2 
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levels is largely in accordance with this lack of response, i.e. most cell lines tested show only 
low baseline levels that are barely changed by either treatment (DLD1, HT29, SW480), 
suggesting that these lines are not actively signaling through Wnt ligand receptors. These 
results also challenge the universal validity of the conclusions drawn by Voloshanenko et al. 
who proposed that colorectal cancers still strongly depend on Wnt ligand exposure for 
maintaining optimal β-catenin signaling levels [26]. Their overall well-performed study 
depended on a thorough analysis of the HCT116 cell line and to a lesser extent on other lines 
such as DLD1. Importantly, the β-catenin mutant HCT116 cell line is nowadays known to carry 
an inactivating mutation in the transmembrane E3 ubiquitin ligase RNF43, which strongly 
sensitizes these cells to exposure by Wnt ligands (see discussion below) [28, 47-49]. As such, 
their study may have unknowingly overstated the importance of Wnt ligand signaling for CRC 
growth in general, warranting a more extensive analysis in a larger cohort of CRC samples and 
cell lines. 
In recent years, Wnt secretion inhibitors, such as the porcupine inhibitor used in our 
study, have emerged as candidate drugs for treating Wnt-driven cancers. Cancers that are 
considered to be especially responsive to these treatments are the ones carrying somatic 
mutations resulting in a persistent presence of Wnt receptors at the cell surface [28, 48]. In 
normal cells, the Wnt/Frizzled receptors are continuously endocytosed and degraded 
following ubiquitination by RNF43 or its close homolog ZNRF3. Both these ubiquitin ligases are 
inhibited in their action by one of four secreted R-spondin proteins [50]. Consequently, 
mutational inactivation of RNF43/ZNRF3 or a strongly increased production of R-spondins 
through the generation of aberrant fusion transcripts, both lead to tumor cells with high levels 
of Wnt/Frizzled receptor at their surface and hyper-responsiveness to Wnt ligands. These 
genetic aberrations have been identified in 10-20% of CRCs and in various other tumor types 
[28, 51, 52], but are to the best of our knowledge not present in HCCs, suggesting that these 
tumors are not prime candidates for treatment with Wnt secretion inhibitors. Nevertheless, 
our analysis shows that most of the HCC cell lines are reduced in their growth to varying 
extents, following both WLS knockdown as well as IWP12 treatment. 
The mechanism of the growth suppression remains more elusive at present. Except for 
the SNU182 cell line, we do see little evidence of β-catenin signaling modulation, suggesting 
that other mechanisms are at play. One possibility is the induction of ER stress resulting from 
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the aberrant accumulation of Wnt ligands in the ER. However, except from increased 
expression of the ER-induced genes CHOP and GRP94, in resp. SNU398 and SNU182, we do 
not see strong evidence that Wnt secretion blockage leads to high levels of ER stress. In 
addition, autophagy did not contribute to the growth suppression either as there was no 
visible change in the pattern of the autophagy marker LC3 following IWP12 treatment. An 
alternative explanation may reside in the reduced secretion of Wnt ligands more commonly 
signaling through β-catenin independent pathways. Activation of these alternative pathways 
has however mainly been shown to affect cellular processes involved in migration and cellular 
polarity and actually to counteract cell proliferation [8]. This “non-canonical” pathway has not 
been extensively studied in liver cancer, but the available literature does indeed support a 
growth suppressive effect [46, 53]. Therefore, interfering with the secretion of this subset of 
Wnt ligands is expected to support cellular growth, which is in contrast to the growth 
suppression that we observe. In line with our results, Covey et al. have shown that knocking-
down PORCN in various tumor cell lines reduced their growth through a Wnt-independent 
pathway [54]. Also in their case no obvious explanation could be uncovered, but both studies 
highlight the importance of considering alternative roles for proteins involved in Wnt 
secretion and their role in regulating cell growth. 
In conclusion, our study shows that the majority of HCC cell lines depend on β-catenin 
signaling for maintaining optimal growth. Extracellular exposure to Wnt ligands has a minor 
contribution to overall β-catenin signaling strength in the β-catenin and AXIN1-mutant cell 
lines. Despite this observation, interfering with Wnt secretion through WLS knockdown or 
inhibition of porcupine function results in reduced growth, indicating that these proteins may 
have alternative roles currently unappreciated. 
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Supplementary Figures and Tables 
 
 
Fig.S1. Wnt/β-catenin signaling activity in CRC cell lines determined by a β-catenin luciferase reporter 
assay (mean ± SD, n=3). 
 
 
 
Fig.S2. SiRNA mediated silencing of β-catenin in CRC cell lines confirmed by western blotting. 
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Fig.S3. Expression levels of remaining “canonical” Wnt ligands in HCC cell lines tested by qRT-PCR 
(mean ± SD, n =3). 
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Fig.S4. Expression levels of “non-canonical” (A) and unclassified (B) Wnt ligands in HCC cell lines 
tested by qRT-PCR (mean ± SD, n =3). 
 
 
Fig.S5. SiRNA mediated silencing of WLS in HCC cell lines tested by western blotting.  
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Abstract 
Background: The Wnt/β-catenin pathway plays a central role in the pathogenesis of most 
hepatoblastomas, i.e. up to 60-80% carry activating CTNNB1 mutations. Hepatoblastomas can 
however also be the first manifestation of familial adenomatous polyposis (FAP). As this is a 
severe disease, it is important for the patient and related family members to firmly exclude 
FAP at an early stage. Current diagnosis largely depends on APC germline mutation detection 
on genomic DNA, which is associated with 10-20% false-negative results. Here, we establish 
and validate a tissue-based β-catenin gene and immunohistochemical analysis, which 
complements germline mutation screening to exclude the diagnosis FAP among HB patients.  
Methods: Tumor tissues of 18 hepatoblastoma patients including 3 FAP cases were subjected 
to CTNNB1 exon3 mutational analysis and immunohistochemistry comparing staining patterns 
for total and exon3 specific β-catenin antibodies.  
Results: Our novel tissue-based method reliably identified all three FAP patients. Their tumors 
were characterized by a wild-type exon3 sequence and a comparable nuclear staining for both 
antibodies. In contrast, the non-FAP tumors carried missense CTNNB1 mutations combined 
with a clearly reduced staining for the exon3 antibody, or complete loss of staining in case of 
lesions with exon3 deletions. 
Conclusion: We have successfully established and validated a novel ß-catenin gene and 
immunohistochemical diagnostic method, which, when combined with routine germline DNA 
testing, allows the exclusion of the diagnosis FAP among HB patients.  
 
Key words: Hepatoblastoma, genetic counseling, familial adenomatous polyposis (FAP), 
Wnt/β-catenin signaling, CTNNB1, APC 
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Introduction 
Hepatoblastoma (HB) is the most common pediatric liver malignancy with an estimated 
incidence of 1 per 100,000 children, mainly affecting children during their first 3 years of life.1,2 
HBs are believed to originate from hepatic progenitor cells that acquire malignant 
transformation during embryogenesis. Histologically they show similarity to immature 
hepatocytes of the developing liver.3,4 Most HBs are believed to be of sporadic nature, but 
about 10-20% have been associated with genetic defects such as Beckwith-Wiedemann 
syndrome (BWS) or familial adenomatous polyposis (FAP).2,5,6 
The Wnt/β-catenin signaling pathway is recognized as having a central role in the 
pathogenesis of hepatoblastomas.4 The β-catenin protein is a key effector of the pathway, 
affecting cellular decisions such as stem cell maintenance and cell proliferation through 
modulating the expression of specific target genes. In normal cells, β-catenin is involved both 
in cell adhesion, when located at the cell membrane, and in transcriptional regulation, when 
present in the nucleus. In the absence of upstream Wnt signaling, β-catenin is phosphorylated 
at N-terminal Serine/Threonine (S/T) residues by a multiprotein complex consisting of the 
adenomatous polyposis coli (APC) tumor suppressor, scaffold proteins AXIN1, AXIN2 and 
AMER1, and the kinases GSK3 and CK1α.7-11 Phosphorylated β-catenin is then ubiquitinated, 
leading to its proteasomal degradation. When cells are exposed to Wnt ligands, this β-catenin 
breakdown complex is temporarily inhibited, leading to the stabilization of β-catenin. As a 
result, it translocates into the nucleus and associates with members of the TCF/LEF family of 
transcription factors, thus regulating the expression of specific downstream Wnt/β-catenin 
target genes. 
In several tumor types, this pathway is constitutively activated due to ‘loss of function’ 
mutations of the APC, AXIN1 or AXIN2 genes leading to inefficient β-catenin degradation and 
its intracellular stabilization. Other tumors carry oncogenic β-catenin (CTNNB1) mutations 
within exon 3 at the N-terminal phosphorylation residues, making the protein more resistant 
to proteolytic degradation. Important for our study, disease-causing mutations in the APC and 
CTNNB1 genes have been shown to occur in a mutually exclusive manner in all tumor types 
studied so far.12 These mutations lead to aberrant stabilization of β-catenin, which 
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constitutively activates downstream Wnt/β-catenin target genes and triggers a genetic 
program resulting in tumor formation.  
HBs are characterized by a high proportion (60-80%) of activating mutations within the 
CTNNB1 gene, either by point mutation or deletions encompassing exon 3.13-22 The deletions 
represent more than 60% of the somatic CTNNB1 mutations and vary in size from small intra-
exonic deletions to larger ones extending up to part of exon 2 or 4. All of them have in common 
that they result in in-frame deletions leading to mutant β-catenin that is resistant to 
degradation.  
Somatic APC mutations have been rarely reported in HBs.14,16,17,23 However, familial 
adenomatous polyposis (FAP) patients carrying a germline APC mutation, present with a 750-
7500-fold increased risk of hepatoblastoma development in comparison to the general 
population.2,24-27 FAP is a hereditary predisposition to develop hundreds to thousands of 
colorectal polyps ultimately leading to colorectal cancer. Untreated, the risk of colorectal 
cancer in FAP patients approaches 100%. The average age when colorectal polyps are 
detected is about 15 years.28 Colonoscopy and surgery in adolescence prevent colorectal 
cancer formation in FAP. When FAP is diagnosed in time, health benefits and increased life 
expectancy can be achieved. Importantly, in children hepatoblastoma can be the first 
manifestation of FAP within a family, especially given the high proportion (10-25%) of de novo 
germline mutations occurring in the APC gene.29-31 This is of importance for the 
management of the child itself and its possible future offspring, but might also have 
implications for yet asymptomatic parents and siblings. For this reason, it has been advocated 
that all HB patients with unknown family history, should be referred for APC germline 
mutation detection,6,32-34 using either combination of currently available methods such as 
next-generation or Sanger sequencing, and multiplex ligation-dependent probe amplification 
(MLPA). These methods will uncover up to 80-90% of disease-causing APC mutations,35,36 
but inherent to any diagnostic method will lead to false-negative results. Examples include 
complex insertions and deletions, chromosomal translocations, or when the patient is a low-
mosaic carrier of the APC mutation.37,38 Moreover, sequence analysis will identify genetic 
variants with uncertain disease-causing relevance. Given the severity of the FAP syndrome a 
thorough exclusion of carrier status is highly desirable. Here, we establish and validate a 
tissue-based β-catenin gene and immunohistochemical analysis, which complements the 
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germline mutation screening to exclude the diagnosis FAP among HB patients. We also discuss 
options how it can be implemented in current clinical practice. 
Materials and Methods 
Patients 
From the period 1995-2013, in total 23 pediatric liver tumors were available for analysis from 
the pathology archive of the Erasmus MC. Tissues were obtained from the initial operative 
procedure and embedded in paraffin after formalin fixation. The medical records and family 
history of patients were analyzed. Patient and tumor characteristics are provided in Table 1. 
All samples were revised by a GI-pathologist (MD) according to a recently proposed consensus 
classification for pediatric liver tumors.39  
Immunohistochemistry (IHC) 
Immunohistochemical analyses for total β-catenin (1:200, clone-14, BD-Transduction 
Laboratories) and non-phosphorylated Ser33/37/Thr41 β-catenin (1:400, #8814, Cell Signaling 
Technology) were performed in an automated stainer (Benchmark-Ultra, Ventana Medical 
Systems, Tucson, AZ). Sections were deparaffinized and pre-treated with standard cell 
conditioning 1 solution (CC1) at 100°C for 64 min, followed by incubation with the specified 
antibodies at 37°C for 60 min. The antibodies were visualized with the OptiView IHC DAB 
detection kit. 
Tumor DNA and RNA isolation and CTNNB1 mutation analysis 
Tumor DNA was extracted by microdissection from formalin-fixed paraffin-embedded (FFPE) 
tissue fragments using proteinase-K and 5% Chelex®-100 Chelating Resin (BioRAD, #1432832), 
as previously described.40 Sequence analysis of CTNNB1 exon 3 was performed by bi-
directional sequencing of PCR-amplified fragments using M13-tailed forward and reverse 
primers (Supplemental Material S1). To test for genomic deletions of CTNNB1 exon3, two 
independent PCRs were performed using primers located within exon2 and exon4. Details of 
the PCR and sequencing reactions and RA isolation are provided in Supplemental Material S1. 
Cell lines 
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Short Tandem Repeat-verified cell lines used in this study were cultured as previously 
described.41 Preparation of paraffin-embedded cell line blocks is described in Supplemental 
Material S1.  
Generation of β-catenin variant expression vectors and transfection 
Expression vectors for N-terminal FLAG-tagged β-catenin variants were generated using the 
pcDNA-5’UT-FLAG vector as basis (kindly provided by Dr. Veronique Lefebvre, Lerner Research 
Institute, Cleveland OH, USA). Wild-type, S33Y and exon3 deleted variants of human CTNNB1 
were cloned using the Gibson assembly method (NEB). The G34V, S37F, T41A and S45P 
variants were generated by Q5® site-directed mutagenesis (NEB), using the wild-type clone as 
basis. Primers are available upon request. All plasmids were fully sequence verified. Next, HEK-
293 cells seeded in 6-well plates were transiently transfected with Fugene-HD (Promega) using 
1μg of plasmid DNA. After two days, cells were lysed in Laemmli sample buffer with 0.1M DTT 
and heated for 5-10 minutes at 95˚C. 
Western blot assay 
The western blot assay and quantification for the FLAG-tag, total and non-phosphorylated 
Ser33/37/Thr41 β-catenin were performed basically as previously described, using all 
antibodies at a 1:1000 dilution.41  
Results 
Patient and tumor characteristics 
In total 23 pediatric liver tumors were included in the study (Table 1), of which 18 were 
hepatoblastomas (HB), 4 hepatocellular carcinomas (HCC) and one hepatocellular adenoma 
(HCA). In accordance with literature, most HB patients were diagnosed during their first three 
years of life. The youngest age at diagnosis was 0.5 years, whereas the oldest patient was 9.7 
years. Hepatoblastoma patients HB-4, HB-14 and HB-29 had been diagnosed with FAP 
previously. The HCC detected in HB-15 was diagnosed in a child belonging to a Li-Fraumeni 
family (LFS), i.e. TP53 germline mutation, whereas HB-32 was observed in a patient with 
Neurofibromatosis type I (NF1). Hypomethylation of LIT1 was reported for patient HB-19, 
although no other signs of BWS were observed.  
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Immunohistochemistry for total β-catenin 
Immunohistochemistry for β-catenin showed nuclear accumulation of β-catenin in one HCC 
(HB-8), while in the remaining three HCCs and the HCA an exclusive membranous pattern was 
observed (Table 2). All HBs showed evidence of nuclear staining, including the ones derived 
from the FAP patients. No nuclear β-catenin was detected in normal pre-existing hepatocytes.  
Table 1. Patient and tumor characteristics 
Sample Gender Age 
(years) 
HB/HCC Pathology Known genetic predisposition 
HB-4 F 5.5 HB Epithelial (too few tumor cells for 
proper evaluation)  
Familial Adenomatous Polyposis 
HB-6 M 0,6 HB Epithelial mixed  
HB-7 M 2,1 HB Epithelial fetal  
HB-8 M 5,9 HCC Classic  
HB-11 F 1.2 HB Epithelial mixed  
HB-13 F 0.5 HB Epithelial mixed  
HB-14 M 3.5 HB Epithelial fetal Familial Adenomatous Polyposis 
HB-15 F 9.7 HCC Classic Belonging to Li-Fraumeni family 
(TP53) 
HB-16 F 15.8 HCC Fibrolamellar  
HB-17 M 9.7 HB Epithelial fetal with low mitotic 
activity 
 
HB-18 F 11.4 HCC Fibrolamellar  
HB-19 F 1.7 HB Epithelial fetal with low mitotic 
activity 
Hypomethylation of LIT1 (no signs 
of BWS) 
HB-20 M 1,1 HB Mixed epithelial-mesenchymal, 
no teratoid 
See note* 
HB-21 M 0.8 HB Epithelial mixed  
HB-22 M 1.0 HB Epithelial mixed  
HB-23 M 9.4 HB Epithelial fetal  
HB-24 M 1.8 HB Epithelial fetal, mitotically active  
HB-25 F 16.3 HCA  See note* 
HB-27 F 7.3 HB Epithelial pleomorphic  
HB-28 F 1.1 HB Mixed epithelial-mesenchymal, 
teratoid 
 
HB-29 M 1.6 HB Mixed epithelial-mesenchymal, 
teratoid 
Familial Adenomatous Polyposis 
HB-30 F 0.8 HB Mixed epithelial-mesenchymal  
HB-32 F 1.1 HB Mixed epithelial-mesenchymal, 
no teratoid 
neurofibromatosis type I 
HCA; Hepatocellular Adenoma, HB; Hepatoblastoma, HCC; Hepatocellular Carcinoma 
CTNNB1 mutation analysis 
Sequence analysis of exon 3 of CTNNB1 succeeded in 22/23 tumors. In 8/18 HBs point 
mutations were detected within or in close proximity to the region encoding the S/T residues 
required for proteolytic breakdown of β-catenin (Table 2). As expected, no mutation was 
detected in all three FAP-derived HBs and in the HCC and HCA samples without nuclear 
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staining. Also no mutation was detected within the single HCC with nuclear accumulation of 
β-catenin.  
Hepatoblastomas are however characterized by a high proportion of genomic deletions 
partially or completely encompassing exon 3,13-21 most of which will be missed by the regular 
exon 3 sequence analysis. Therefore, we attempted two genomic PCRs on DNA isolated from 
the FFPE samples, using a common forward primer in exon 2 and two reverse primers, 
respectively at the 5’- and 3’-side of exon 4. The latter can detect the reported deletions. 
Table 2. CTNNB1 mutational status and β-catenin IHC pattern of pediatric liver cancers 
Sample 
HB 
or 
HCC 
genetic 
predisposition 
Nucleotide change 
detected 
 in genomic DNA 
RNA 
alteration Amino Acid  
alteration 
C-ter β-cat IHC S33/37/T41 β-cat IHC 
HB-15 HCC LFS None   Membrane only Membrane only 
HB-16 HCC  None   Membrane only Membrane only 
HB-18 HCC  None   Membrane only Membrane only 
HB-25 HCA  None   Membrane only Membrane only 
HB-4 HB 
FAP  
p.Q1062* 
None 
 
 Nuclear Nuclear 
HB-14 HB FAP  p.R1114* none   Nuclear Nuclear 
HB-29 HB 
FAP  
p.Q1062* 
None 
 
 Nuclear Nuclear 
HB-6 HB  c.97T>C  p.S33P Nuclear Nuclear 
HB-17 HB  c.86C>T + c.94G>T 
 
p.S29F + p.D32Y Nuclear 
Moderate 
Nuclear 
HB-22 HB  c.94G>A  p.D32S Nuclear Nuclear 
HB-7 HB  c.101G>T  p.G34V Nuclear Faintly nuclear 
HB-13 HB  c.101G>T  p.G34V Patchy nuclear Faintly nuclear 
HB-20 HB  c.101G>T  p.G34V Nuclear Faintly nuclear 
HB-21 HB  c.101G>T  p.G34V Nuclear Faintly nuclear 
HB-28 HB  c.121A>G   p.T41A Nuclear Patchy nuclear 
HB-8 HCC  None r.14_241del p.A5_A80del Nuclear Negative 
HB-11 HB  Not analyzable r.14_241del p.A5_A80del Nuclear Negative 
HB-19 HB LIT1 None ±215 bp del p.? Nuclear Negative 
HB-23 HB  None   Nuclear Membrane only 
HB-24 HB  None r.14_241del p.A5_A80del Nuclear Negative 
HB-27 HB  None   Nuclear Membrane only 
HB-30 HB  c.98_238del r.98_238del p.G34_A80del Nuclear Negative 
HB-32 HB NF1 c.14-202_241+69del r.14_241del p.A5_A80del Nuclear Negative 
At large, four different staining patterns were observed using the C-terminal and S33/37/T43 β-catenin antibodies. Combined 
with the genomic mutation analysis the most likely β-catenin-related mechanism contributing to tumor formation is color-
coded as follows: 
No evidence of mutations leading to β-catenin activation,   APC mutation or β-catenin D32/S33 amino acid alterations,    β-
catenin G34 amino acid alteration, β-catenin exon 3 deletion.  
”Nuclear” means a combination of nuclear, cytoplasmic and membranous staining. “Negative” means no staining visible in 
tumor cells. 
The following abbreviations are used: HCA-Hepatocellular Adenoma, HB-Hepatoblastoma, HCC-Hepatocellular Carcinoma, 
FAP-familial adenomatous polyposis, LFS-Li-Fraumeni syndrome, LIT1-LIT1 hypomethylation, NF1-Neurofibromatosis Type-1, 
IHC-Immunohistochemistry. 
Immunohistochemical identification of β-catenin alterations 
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Given the poor quality of DNA extracted from FFPE material, we sought for an alternative 
method to identify samples with genomic CTNNB1 deletions. All these mutations generate 
mutant β-catenin proteins that are more resistant to proteolytic breakdown. Hence, the great 
majority of β-catenin protein present within a CTNNB1 mutant cell is represented by the 
mutant protein. This will be especially the case for the nuclear compartment as most of the 
wild-type protein is prevented from entering the nucleus through degradation by the 
APC/AXIN breakdown complex. We hypothesized that an immunohistochemical analysis using 
a β-catenin antibody specifically recognizing the N-terminal S/T residues, could distinguish 
between APC- and β-catenin mutant tumors. In APC-mutant tumors wild-type β-catenin 
accumulates in the nucleus that can still be detected by such an antibody, whereas (partial) 
deletion or mutation of the β-catenin S/T residues would prevent detection.  
To validate this approach, we first tested a panel of cell lines with known CTNNB1 mutations 
using a C-terminal β-catenin antibody in comparison with one raised against a peptide 
corresponding to residues surrounding S37. Western blot analysis using the C-terminal 
antibody robustly demonstrated β-catenin in all cell lines, including the shortened mutant 
product present in HepG2 cells (Figure 1A). The non-phospho S33/37/T41 antibody readily 
detected the wild-type β-catenin present in the APC-mutant line SW480. Also the S45 mutant 
β-catenin present in HCT116 and LS174T was demonstrated at high intensity compared with 
the C-terminal antibody. In contrast, the exon 3 deleted product of HepG2 and S37/T41 
alterations completely abrogated detection, while S33 and G34 alterations resulted in reduced 
detection. The latter may represent binding to wild-type β-catenin present in these cells 
and/or retained affinity for the mutant protein.  
To investigate residual binding affinity for mutant β-catenin by the S33/37/T41 antibody, we 
transiently expressed N-terminal FLAG-tagged β-catenin variants in HEK-293 cells (Figure 1B). 
Deletion of exon 3, and S37F/T41A alterations completely abrogated binding. In contrast, the 
S33Y variant was identified at comparable levels to the wild-type protein, while the G34V 
variant is detected with ±40% reduced signal intensity. In conclusion, the S33/37/T41 antibody 
retains affinity for S33/G34 alterations when present in denatured form on western blot, while 
S37/T41 changes and deletion of exon 3 prevent its binding. 
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Figure 1. Western blot validation of the non-phospho S33/37/T41 β-catenin antibody. (A) Western blot analysis of one APC 
mutant and eight β-catenin mutant cell lines using a C-terminal β-catenin antibody (upper lanes) in comparison with one 
raised against a peptide corresponding to residues surrounding S37 (lower lanes). Amino acid alterations and zygosity status 
are depicted on top. Name of cell line is in brackets. Deletion of exon 3 and alterations of S37 and T41 abrogate binding. 
Reduced signal for S33 and G34 variants suggests lowered affinity, although residual binding to remaining wild type protein 
cannot be formally excluded. S45 changes are largely unaffected. Proportional binding of the S33/37/T41 antibody is shown 
on the right with the ratio of the APC-mutant SW480 cell line set arbitrarily to one. (B) Transient expression of FLAG-tagged 
wild type and S/T mutant β-catenin variants shows that S33Y β-catenin can still be recognized by the S33/37/T41 antibody. 
The G34V variant shows a ±40% reduced signal intensity. The other variants confirm the cell line analysis. The weaker band 
with lower molecular weight visible in all lanes is the endogenous β-catenin protein produced by HEK-293 cells. Proportional 
binding of the S33/37/T41 antibody is shown on the right with the ratio of the wild type protein set arbitrarily to one. 
Next, we evaluated this antibody for immunohistochemical purposes using paraffin blocks 
containing formalin-fixed β-catenin mutant cell lines. In line with the western blot data, S45 
mutant HCT116 and LS174T showed a comparable staining pattern for both antibodies (Figure 
2). In strong contrast, all other β-catenin mutant lines showed a clearly reduced overall 
staining using the S33/37/T41 antibody. The S37C and T41A mutant lines are completely 
negative. In the S33 mutant lines SW48 and SW1573 nuclear staining can be observed in some 
cells, although with reduced intensity. The exon 3 deletion mutant HepG2 line showed an 
exclusive membranous staining, most likely resulting from detection of the remaining wild-
type protein. Also in the G34V mutant Huh6 line no obvious nuclear staining was observed. 
Surprisingly, IHC staining of this variant is much weaker than anticipated from the western 
blot analysis, most likely resulting from reduced antibody affinity when present in its “native” 
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form in FFPE sections and/or partial phosphorylation of S37/T41 residues. In conclusion, the 
S33/37/T41 β-catenin antibody can reliably identify the cell lines with exon 3 CTNNB1 
mutations, with the exception of S33 and S45 alterations.  
 
Figure 2. Immunohistochemical validation of the non-phospho S33/37/T41 β-catenin antibody. Formalin-fixed and paraffin-
embedded cell pellets of the β-catenin mutant cell lines were stained with the C-terminal (top rows) and S33/37/T41 (bottom 
rows) β-catenin antibodies. Staining patterns are largely in line with western blot analysis with the exception of the relatively 
weak staining pattern observed for the G34V protein present in Huh6. HepG2 shows an exclusive membranous staining with 
the S33/37/T41 antibody, most likely reflecting the remaining wild type protein. Both S33 mutant cell lines retain some 
nuclear detection, albeit slightly reduced. S45 variant cell lines show identical staining patterns with both antibodies. Original 
magnification 400x. 
Next, the S33/37/T41 antibody was applied to the tumor sections and compared with that of 
total β-catenin (Figure 3, Supplemental Figure S1). At large, four different staining patterns 
were observed. The tumors with exclusively membranous β-catenin were stained in an 
identical fashion with the S33/37/T41 antibody (Figure 3A,B and S1). Importantly, all three 
FAP-associated lesions showed basically identical staining patterns with both antibodies as 
well, i.e. a high proportion of tumor cells showing evidence of nuclear accumulation (Figure 
3C,D and S1). This pattern was also observed in lesions with D32 and S33 mutations, albeit 
with slightly lower intensity for the S33/37/T41 antibody (Figure 3E,F and S1). The third 
pattern is observed in HBs with G34V mutation. These showed a strongly reduced overall 
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staining using the S33/37/T41 antibody. However, occasionally tumor cells with nuclear 
staining can be clearly observed, especially in regions with heavy staining for total β-catenin 
(Figure 3G,H and S1). This pattern was also observed in HB-28, the only lesion with a T41 
mutation, in which a heavy overall β-catenin staining is accompanied by occasional nuclear-
positive cells using the S33/37/T41 antibody (Figure S1). As the T41A alteration cannot be 
detected by this latter antibody, the nuclear staining most likely results from wild-type protein 
induced to enter the nucleus. Lastly, in both HBs with proven genomic exon 3 deletions 
virtually no tumor cell staining was detectable (Figure 3I,J and S1). A similar pattern was also 
identified in six additional samples with no identifiable point mutation, suggesting that in total 
7 out of 18 HB samples and one HCC sample carry genomic exon 3 deletions. In two of these 
samples some residual membranous staining was visible (HB-23 and HB-27, Figure S1). 
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Figure 3. Immunohistochemical identification of β-catenin alterations in tumor samples. 
FFPE sections of pediatric liver tumors were stained with the C-terminal (left column) and S33/37/T41 (right column) β-
catenin antibodies. (A,B) Comparable membranous staining in the fibrolamellar hepatocellular carcinoma (HB-18) with no 
evidence of β-catenin mutation or activation. (C,D) HB-29 derived from a FAP patient shows identical nuclear and cytoplasmic 
accumulation of wild type β-catenin using both antibodies. (E,F) In sample HB-6 a p.S33P mutation was detected, which shows 
nuclear staining with both antibodies, albeit slightly weaker using the S33/37/T41 antibody. (G,H) Sample HB-20 carrying a 
p.G34V mutation shows clear nuclear β-catenin accumulation in tumor sections. Staining with the S33/37/T41 antibody is 
strongly reduced or entirely lost in tumor cells, while normal structures on the left are stained in an identical fashion. (I-L) 
The strong nuclear and cytoplasmic staining of sample HB-30 with genomic deletion of exon 3, is completely lost using the 
S33/37/T41 antibody. Original magnification 200x. 
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Confirmation of exon 3 deletion by RT-PCR 
To confirm that these latter samples indeed express mutant CTNNB1 mRNA (partially) lacking 
exon 3, we performed RT-PCR on RNA isolated from paraffin sections. Successful RNA isolation 
was possible in 6 samples. In 4 out of 6 samples a 127 bp product was observed indicative of 
a complete absence of exon 3 (Figure 4). In sample HB-30 a shortened 214 bp product was 
observed, which after sequencing was confirmed to carry the same intra-exonic 141 bp 
deletion already observed during the genomic DNA analysis. Sample HB-19 showed a 
shortened reproducible product of about 140 bp, indicating that an approximate 215 bp 
deletion is present in the cDNA. In conclusion, all 6 samples with negative S33/37/T41 β-
catenin nuclear staining and absence of exon 3 point mutation, showed evidence of (partial) 
exon 3 deletion on RNA level. 
 
 
 
 
 
Discussion 
Most HBs are believed to be of sporadic nature, but about 10-20% have been associated with 
genetic defects such as Beckwith-Wiedemann syndrome or familial adenomatous 
polyposis.2,5,6 For this reason, it has been advocated that all HB patients with unknown family 
history, should be referred for genetic counseling.6 Among the genetic syndromes associated 
with hepatoblastoma development, FAP is one of the most common with an estimated 
frequency between 5-10%.2,16 As this is a severe disease, it is important for the patient itself 
but also for yet asymptomatic family members to determine their carrier status at an early 
stage. Especially a firm exclusion of an underlying APC germline mutation will prevent the 
unexpected emergence of polyposis or colorectal cancer at a later stage. Current diagnosis 
largely depends on APC germline mutation detection on genomic DNA, but inherent to any 
Figure 4. Confirmation of exon 3 deletion 
by RT-PCR. 
RNA was isolated from 6 HBs with 
immunohistochemical evidence of (partial) 
exon 3 loss, and subjected to RT-PCR using 
primers in exon 2 and 4. In 4 out of 6 samples 
a 127 bp product was observed indicative of 
a complete absence of exon 3 (HB-8, HB-11, 
HB-24 and HB-32). Sample HB-19 showed a 
reproducible shortened product of 
approximately 140 bp (*). In sample HB-30 
the intra-exonic 141 bp genomic deletion 
was confirmed on RNA level. Positive control 
is RNA isolated from normal tissue. 
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diagnostic method this will occasionally lead to false-negative results. In case of classical 
polyposis phenotypes the APC mutation detection rate is around 80-90%,35,36 meaning that a 
possible 10-20% of FAP patients may be missed by routine genetic testing. This leads to the 
highly undesired scenario in which apparent APC mutation negative patients develop 
polyposis later. For this reason, Aretz et al. proposed for all APC-negative HB patients to 
undergo colonoscopy around age 15 and one at age 25, and to also offer colonoscopy to the 
parents.2 The downside of this approach is that many genuine APC-negative individuals will be 
exposed to unneeded medical investigations, associated with anxiety and considerable costs. 
Here, we establish and validate a tissue-based β-catenin gene and immunohistochemical 
analysis that complements the germline mutation screening to exclude the diagnosis FAP 
among HB patients. Following successful confirmation in an independent series, its application 
will lead to a near-complete exclusion of FAP among HB patients.  
Our method is based on the observation that tumor-driving CTNNB1 and APC mutations occur 
in a mutually exclusive nature in all tumor types studied so far.12 As such, the identification of 
a somatic activating CTNNB1 mutation in a HB patient directly reduces the risk of carrying a 
germline APC mutation to that of the general population. By combining mutational analysis of 
CTNNB1 exon3 and IHC comparing staining patterns for total and S33/37/T41 β-catenin, we 
could reliably identify all three FAP patients in our cohort of 18 HB cases. Their tumors are 
characterized by a comparable nuclear staining for both antibodies and wild-type exon 3 
sequence. In fact, the IHC analysis by itself can already select a large proportion of HBs that 
carry an activating CTNNB1 mutation, and thus have no increased risk of an underlying APC 
germline mutation. Our epitope and immunohistochemical analysis suggests that all amino 
acid alterations and genomic deletions encompassing the G34-T41 region would prevent or 
strongly reduce binding of the S33/37/T41 antibody. Reviewing the literature for the type of 
CTNNB1 mutations reported in HBs, about 85% of mutations (198/234) fulfil this criterion.13-
21 The main exceptions are D32/S33 amino acid alterations, while S45 mutations are rarely 
observed in HB (3/234). Although the IHC analysis can already identify most HB patients with 
CTNNB1 mutations, we nevertheless propose to also include the exon 3 mutation analysis on 
tumor DNA. This will identify point mutations outside the epitope of the S33/37/T41 antibody 
(D32, S33 and S45), and provides a confirmation of the CTNNB1 mutational status.  
Excluding FAP carriers among hepatoblastoma patients 
93 
 
As CTNNB1 mutations are the predominant mutation in pediatric liver cancers (up to 80%), 
most patients are unlikely carriers of a germline APC mutation. A small subset of cancers arise 
without apparent β-catenin activation, i.e. the ones with exclusively membranous β-catenin 
staining and wild-type sequence. As it is highly unlikely that such a β-catenin nuclear-negative 
tumor arises in a FAP patient, these are also unlikely to carry a germline APC mutation. 
Anecdotally, somatic APC and AXIN1/AXIN2 mutations have been reported in 
hepatoblastomas that also lead to tumors in which wild-type β-catenin accumulates in the 
nucleus.15,16,22 These rare tumors would lead to APC germline negative patients, whereas the 
tumor analysis indicates an underlying FAP syndrome. Below we discuss how to deal with this 
small subset of HB tumors. 
How to implement our method in current clinical practice? As HBs can be a manifestation of 
several genetic syndromes, all patients should be offered genetic counseling and evaluated 
for syndromic features such as the macrosomia and organomegaly associated with BWS. In 
the absence of such features and a negative family history, a genetic mutation analysis is 
warranted. This should include at least the APC gene, but may also include other genetic 
cancer predisposition syndromes such as LFS and NF1.42,43 Simultaneous with or preceding the 
counseling process, we propose to combine a routine histopathological evaluation of the 
tumor tissue with both β-catenin stainings described here. In addition, tumor DNA should be 
isolated from the FFPE-material and evaluated for CTNNB1 exon3 mutations, which can also 
be done as part of a larger next-gen sequencing panel.  
In most cases the genetic and tumor tissue analyses will corroborate each other. Identification 
of a germline APC mutation will be accompanied by a comparable staining with both 
antibodies and wild-type CTNNB1 sequence in the tumor tissue, while APC germline negative 
cases will show somatic activating CTNNB1 mutations and reduced staining with the 
S33/37/T41 antibody. However, given the approximate 10-20% false-negative APC mutation 
analyses, occasionally tumors will be identified showing nuclear accumulation of wild-type β-
catenin without an identifiable APC germline mutation. As these cases are at increased risk to 
develop FAP at a later stage, colonoscopies of the index patient and its parents can be 
performed, as suggested by Aretz et al.2 Using our diagnostic method, this can however be 
restricted to the subset of APC germline negative patients that express wild-type β-catenin in 
the tumor. Alternatively, the somatic mutation analysis of these tumors can be extended to 
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identify inactivating somatic AXIN1/2 or APC mutations. When AXIN1 or AXIN2 mutations are 
identified this also excludes the diagnosis FAP. In the case of a “somatic” APC mutation more 
caution is needed as this may indicate a missed germline mutation that is present for example 
in a low-mosaic fashion in the patient. 
Our approach can also be extended to other extracolonic FAP manifestations, such as 
pilomatricomas and desmoids. These lesions are also characterized by high frequencies of 
somatic β-catenin mutations, meaning that most are of sporadic nature.44-50 About one third 
of CTNNB1 mutations reported for desmoids are at codon S45, which are missed by the IHC 
method described here, but if desired this analysis can be extended by including an antibody 
specifically recognizing this epitope (e.g. #19807, Cell Signaling technology). 
In conclusion, we have successfully established and validated a novel ß-catenin gene and 
immunohistochemical diagnostic method, which following confirmation in an independent 
series, allows the near-complete exclusion of the diagnosis FAP among HB patients, when 
combined with routine germline DNA testing.   
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Supplemental Methods 
Detailed PCR and sequencing protocol for CTNNB1 mutation analysis 
PCR products from tumor DNA were generated in a 15µl reaction mixture including 1µl of each 
primer (10µM) and 7.5µl KAPA2G Robust Hot Start ReadyMix (KAPA-Biosystems, #KK5702). 
The PCR reaction was performed with a thermocycler (Biometra, Göttingen, Germany) with 
an initial denaturation step (95˚C) for 3 min., followed by 35 cycles of denaturation (95˚C) for 
15 sec., annealing (60˚C) for 15 sec. and extension (72˚C) for 15 sec. PCR products were 
sequenced with M13-forward primer and M13-reverse primers using the BigDye® Terminator-
v3.1 Cycle Sequencing kit (Applied Biosystems™, ThermoFisher Scientific, Waltham, MA, USA). 
Sequences were analyzed on an ABI-3730 DNA Analyzer (Applied Biosystems™). Data were 
analyzed with Mutation Surveyor® software (SoftGenetics) and compared with the public 
sequences of GenBank (NG_013302.1 or NM_001904.3) 
Tumor RNA isolation and analysis 
RNA was extracted by microdissection from FFPE tissue fragments using the RNeasy®-FFPE Kit 
(Qiagen, Cat No./ID: 73504) according to the manufacturer’s instructions. cDNA was 
generated basically according to the manufacturer’s instructions (Thermo Scientific, #K1612) 
using 20pmol of M13-tailed gene-specific reverse primers CTNNB1-Ex3del-R4.1 and CTNNB1-
Ex3-4del-R4.2 (Supplemental Table 2). Next, to detect CTNNB1 deletions at cDNA level, two 
independent PCRs were performed with the FAM-labeled CTNNB1-Ex2-F forward primer and 
M13R-CTNNB1-Ex3del-R4.1 and M13R-CTNNB1-Ex3-4del-R4.2 reverse primers. PCR 
conditions were as described above. 
Cell lines 
Cell lines SW1573, SW48, SW480, Huh6, SNU398, HCT116 and HEK-293 were cultured in 
Dulbecco’s modified Eagle medium (DMEM) (Invitrogen-Gibco) complemented with 10% fetal 
calf serum (FCS) (Hyclone, Lonan, Utah). A427 and LS174T were cultured in RPMI-1640 
medium (Invitrogen-Gibco), respectively with 10% and 5% FCS. HepG2 was cultured on 
fibronectin/collagen/albumin-coated plates (AthenaES) in Williams-E medium (Invitrogen-
Gibco) complemented with 10% FCS. All media were supplemented with 100IU/ml penicillin 
and 100μg/ml streptomycin. Identity of all cell lines was confirmed by Short Tandem Repeat 
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genotyping. CTNNB1 mutation status was confirmed in all cell lines by Sanger sequencing and 
was consistent with those reported at COSMIC (http://cancer.sanger.ac.uk).38 
Preparation of paraffin blocks from cell lines 
For each cell line 2-5 15cm tissues culture dishes were grown to near-confluency. Next, the 
cells were scraped with a rubber policeman, collected and centrifuged. The resulting pellet 
was washed with PBS once, followed by the addition of 15ml of PBS-buffered 10% formalin. 
After at least 2 hrs fixation, cells were transferred to 2ml tubes and spun down for 3 minutes 
at 300G. The cell pellet was mixed with a 1% agarose solution in PBS, maintained at 50˚C 
before use, by gently stirring with a pipette tip or flame-closed Pasteur pipette. Following a 
cool-down on ice, a small hole was burned in the bottom using a heated needle, after which 
the agarose plug was released by pressurized air. The agarose plug was placed in buffered 
formalin again and embedded in paraffin according to routine protocols. Fixation time for all 
cell lines was at least 6hrs and a maximum of 24hrs. 
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Supplementary Tables and Figures 
Supplemental Table 1  Primer sequences for amplifying genomic CTNNB1 
Primer Nucleotide sequence 
Expected size 
(without M13) 
CTNNB1-AMPL7153305149-Ex3-F M13F-CTGATTTGATGGAGTTGGACATGG 160 
CTNNB1-AMPL7153305149-Ex3-R M13R-TCCACATCCTCTTCCTCAGGATT  
CTNNB1-Ex2F1 GAAAATCCAGCGTGGACAATG 980 
CTNNB1-Ex4R2 TGCCCTCATCTAATGTCTCAG  
CTNNB1-Ex2F2 TGGACAATGGCTACTCAAG 945 
CTNNB1-Ex4R1 AACATAGCAGCTCGTACCCTC  
M13F TGTAAAACGACGGCCAGT  
M13R CAGGAAACAGCTATGACC  
 
 
Supplemental Table 2  Primer sequences for analyzing CTNNB1 cDNA 
Primer Nucleotide sequence 
Expected wild type 
product size (bp) 
CTNNB1-Ex2-F GTTTTGAAAATCCAGCGTGGACAAT  
CTNNB1-Ex3del-R4.1 M13R-TCATCTAATGTCTCAGGGAACATAGCAGCTCGTACCCTC 355 
CTNNB1-Ex3del-R4.2 M13R-AGTTTTGTCAGTTCAGGGATTGCA 517 
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Supplemental Figure 1.  
Immunohistochemical identification of β-catenin alterations in remaining tumor samples. 
FFPE sections of remaining pediatric liver tumors were stained with the C-terminal (top 
rows) and S33/37/T41 (bottom rows) β-catenin antibodies. Identified mutation status is 
reported for each sample. 
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Wnt/β-catenin signaling is important for the proper development of all multicellular 
organisms and is a critical regulator for most types of epithelial stem cells. Therefore, it is not 
surprising that dysregulation of Wnt/β-catenin signaling is observed in many cancers (1). Also, 
in hepatocellular carcinoma (HCC), frequently aberrant activation of this signaling pathway 
has been identified, for example by acquired activating β-catenin or inactivating AXIN1 
mutations. Besides direct mutational activation, β-catenin signaling can also be modulated 
through various other mechanisms. One example is provided by the viral proteins expressed 
during chronic HBV or HCV infection, both prominent risk factors for the development of HCC. 
In Chapter 2, we comprehensively reviewed the current biomedical knowledge on the role of 
the Wnt/β-catenin signaling pathway in the progression from chronic hepatitis C infection to 
cirrhosis and HCC, and explored potential hypotheses as to the mechanisms involved. In this 
review, we first summarize the relative mutation frequencies of Wnt/β-catenin signaling 
elements in HCC cohorts reported previously. Activating mutations in CTNNB1 are the most 
prevalent in general and especially in HCV-related HCC (>25%). Next, we discuss the mutual 
interaction between HCV infection and Wnt/β-catenin signaling. Both the HCV viral core and 
NS5A proteins provoke activation of Wnt/β-catenin signaling. HCV infection is also associated 
with increased EGFR and FGF signaling, both contributing to the cirrhotic and tumorigenic 
process by enhancing the PI3K/AKT and Ras/Raf/MEK/ERK pathways, but also by further 
increasing β-catenin signaling. Thus, HCV infection exploits multiple mechanisms leading to 
enhanced β-catenin signaling. In turn, stimulated Wnt/β-catenin signaling paves the way for 
progression of hepatitis C during inflammation and fibrosis to eventually cirrhosis and HCC.  
Despite of the development of a large number of molecular inhibitors targeting Wnt/β-
catenin signaling during recent decades, little is known about the response to these inhibitors 
of HCC cells carrying different genetic mutations relevant to aberrantly activated Wnt/β-
catenin signaling. In Chapter 3, we tested the Wnt secretion inhibitor IWP12 in our HCC cell 
line panel. First, using siRNA mediated knock-down of β-catenin we showed that the majority 
of HCC cell lines were dependent on β-catenin signaling for optimal cell growth. Blocking Wnt 
secretion by treatment with the IWP12 porcupine inhibitor reduced growth of most HCC cell 
lines, which was confirmed by knock-down of WLS essential for Wnt secretion. However, none 
of the CTNNB1 and AXIN1 mutant HCC cell lines were affected at the β-catenin signaling level. 
This was shown both by a β-catenin reporter assay and RNA level of AXIN2 (a well-known 
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target gene of β-catenin signaling) upon alterations of Wnt ligand exposure, neither by 
blocking Wnt secretion using IWP12 nor by the addition of WNT3A ligand. This suggests that 
the expressed oncogenic β-catenin or mutant AXIN1 proteins determine overall signaling 
levels in a dominant fashion. Furthermore, IWP12 treatment did not induce autophagy or 
endoplasmic reticulum (ER) stress, which may have resulted from the accumulation of Wnt 
ligands within the ER. In accordance with our results, Covey et al. also have shown that 
knocking down porcupine in various tumor cell lines reduced their growth through a Wnt-
independent pathway with no clear explanation revealed (2). Similarly, most CRC cell lines 
tested as a comparison in various assays, showed dependency on β-catenin signaling and 
inhibition of cell growth after Wnt secretion blockage, either by IWP12 or knockdown of WLS. 
In accordance with liver cancer cell lines, the growth inhibition was not associated with clear 
alterations in Wnt/β-catenin signaling regardless of the underlying APC or CTNNB1 mutations. 
Our results suggest that most colorectal and liver cancers with mutations in components of 
the β-catenin degradation complex do not strongly rely on extracellular Wnt ligand exposure 
to support optimal growth. Blocking Wnt secretion may however aid in tumor suppression 
through alternative routes currently unappreciated. 
In chapter 4, we investigated a second class of molecular inhibitors of β-catenin signaling, 
that is the Tankyrase inhibitors, and we determined in more detail to which extent AXIN1 and 
AXIN2 are involved in the regulation of β-catenin signaling in HCC. Together with APC and the 
kinases GSK3 and CK1α, these proteins form the core of the β-catenin break-down complex. 
Loss-of-function mutations in AXIN1 and AXIN2 are observed in 10.4% and 3.3% of HCC 
patients respectively (3). Mutated AXIN1 or AXIN2 are expected to lead to enhanced Wnt/β-
catenin signaling, although this has been debated (4-6). The AXIN proteins themselves are also 
under proteolytic control and are rapidly degraded following poly-ADP-ribosylation by 
Tankyrase enzymes. Hence, Tankyrases have emerged as therapeutic targets as their 
inhibition theoretically leads to AXIN accumulation, ultimately expected to result in reduced 
β-catenin signaling and tumor cell growth. In this chapter, we first investigated in more detail 
to what extent AXIN1 and AXIN2 are involved in regulating β-catenin signaling in our panel of 
HCC cell lines. Western blot analysis showed that both AXINs were expressed at low levels in 
the non-mutant and AXIN1 mutant cell lines, while they were readily detectable in the CTNNB1 
mutant ones. Tankyrase inhibition for one day resulted in a clear accumulation of AXIN2 
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exclusively in the CTNNB1 mutant lines. Surprisingly, no clear accumulation of AXIN1 was 
observed in any of the lines. Mechanistically, this may be explained by the RNA expression 
levels that we observed for both genes, as AXIN1 was expressed at considerably lower levels 
than AXIN2 in all HCC lines. Recently, Thorvaldsen et al. showed that sustained protein 
translation is required for AXIN accumulation (6). Indirectly this also implies that higher AXIN2 
RNA expression levels will lead to a more robust protein accumulation, which is in line with 
our results. Next, we investigated to what extent both AXIN proteins are involved in regulating 
β-catenin signaling in HCC. We knocked-down their expression using siRNA, with APC knock-
down as a positive control. Simultaneous knock-down of both AXINs in the non-mutant lines 
indicates that they work in a complementary fashion to regulate β-catenin signaling. As 
expected, in the AXIN1 mutant lines AXIN1 knock-down had no clear effect, while AXIN2 
knock-down resulted in a similar activation of β-catenin signaling as APC knock-down. These 
results show that both AXIN proteins are involved in β-catenin regulation in HCC, arguing 
against some reports that suggest that AXIN1 mutations do not contribute to HCC tumor 
growth through enhancing β-catenin signaling (4, 5). Lastly, we tested whether Tankyrases 
represent an attractive target to inhibit the growth of HCCs. B-catenin signaling was barely 
affected following Tankyrase inhibition in the CTNNB1 mutant cell lines, while it was clearly 
diminished in all AXIN1 and most non-mutant lines. Despite this inhibition in β-catenin 
signaling the growth and colony formation capabilities of these cell lines were at most slightly 
inhibited by Tankyrase inhibition. These results suggest that Tankyrase inhibitors are not likely 
going to efficiently affect the growth of HCCs. 
In chapter 5, we uncovered the importance of oncogenic serine-threonine kinase 
receptor associated protein (STRAP) to sustain HCC cell growth through enhancing Wnt/β-
catenin signaling. STRAP harbors seven WD40-repeat domains and is considered to be a 
scaffolding protein without enzymatic function that exerts regulatory functions on a variety 
of cellular processes. Using immunohistochemistry we showed that STRAP was up-regulated 
in HCC, as previously reported in breast (7), lung (8) and colorectal cancers (8, 9). To study the 
function of STRAP in more detail, we applied siRNA mediated knock-down on our panel of HCC 
cell lines and generated knock-out clones using CRISPR/Cas9 gene editing. Loss of STRAP 
resulted in a strongly impaired growth, altered cell cycle progression and reduced capacity to 
form colonies from single cells. Furthermore, our findings indirectly (β-catenin target gene 
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expression) and directly (β-catenin signaling activity using reporter assays) provide evidence 
that the abundance of STRAP stimulates Wnt/β-catenin signaling activity, thereby supporting 
optimal HCC cell growth. Mechanistically, others have shown that STRAP binds to the catalytic 
site of GSK3β via its WD40 domain region, eliciting the compromised ability of GSK3β to 
phosphorylate the (N-terminal) serine/threonine residues encoded by exon3 of β-catenin (10, 
11). Accordingly, we observed reduced levels of active β-catenin in STRAP knock-out clones of 
Huh6 and PLC/PRF/5. In these lines we also observed reduced levels of C-terminal 
phosphorylated β-catenin at S675, which is expected to result in more ubiquitination of β-
catenin and less recruitment of transcriptional co-activators (12-14). Nevertheless, different 
from CTNNB1 mutant Huh6 and AXIN1 mutant PLC/PRF/5 cell lines, Huh7 apparently does not 
share any of the above rationales, despite showing reduced β-catenin signaling following 
STRAP loss. This indicates that STRAP may modulate β-catenin signaling through alternative 
routes that remain to be uncovered. RNA sequencing analysis of STRAP knock-out clones and 
controls thereof, also suggests that STRAP could facilitate stem cell self-renewal while 
simultaneously attenuating cell differentiation. The same analysis also revealed that besides 
Wnt/β-catenin signaling, many other signaling pathways and metabolic processes were 
affected following STRAP loss, which is in line with reports demonstrating STRAP’s role in 
regulating other signaling pathways (15-17). Taken together, our results show that STRAP 
expression is increased in hepatocellular cancers, and provides growth advantage to the 
tumor cells, among others by enhancing Wnt/β-catenin signaling. 
In chapter 6, we extended our study to hepatoblastoma (HB), a potentially malignant 
pediatric liver cancer. The Wnt/β-catenin pathway plays a central role in the pathogenesis of 
these tumors, i.e. up to 60-80% carry activating CTNNB1 mutations. Hepatoblastomas can 
however also be the first manifestation of familial adenomatous polyposis (FAP), which is a 
hereditary predisposition to develop hundreds to thousands of colorectal polyps ultimately 
leading to colorectal cancer. FAP patients carry germline APC gene mutations leading to 
enhanced β-catenin signaling following somatic mutation of the remaining wild-type APC 
allele. As this is a severe disease, it is important for the patient and related family members to 
firmly exclude FAP at an early stage. Current diagnosis largely depends on APC germline 
mutation detection on genomic DNA, which is associated with 10-20% false-negative results. 
In this chapter, we establish and validate a tissue-based β-catenin gene and 
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immunohistochemical analysis, which complements germline mutation screening to exclude 
the diagnosis FAP among HB patients. Important for our study, tumor-driving CTNNB1 and 
APC mutations occur in a mutually exclusive fashion in all tumor types. Hence, the 
identification of a somatic activating CTNNB1 exon3 mutation in a HB patient directly reduces 
the risk of carrying a germline APC mutation to that of the general population.  CTNNB1 
mutation analysis in HBs is however complicated by a high proportion (>60%) of genomic 
deletions, varying in size from small intra-exonic deletions to larger ones extending up to part 
of exon 2 or 4, which can easily be missed using routine mutation analysis. Here we show that 
by combining CTNNB1 exon3 mutational analysis and immunohistochemistry comparing 
staining patterns for total and exon3 specific β-catenin antibodies, we can faithfully diagnose 
the great majority of hepatoblastomas. Among 18 lesions, all three FAP tumors were 
characterized by a wild-type exon3 sequence and a comparable nuclear staining for both 
antibodies. In contrast, the non-FAP tumors carried missense CTNNB1 mutations combined 
with a clearly reduced staining for the exon3 antibody, or complete loss of staining in case of 
lesions with exon3 deletions. When this method is combined with routine germline DNA 
testing, it allows the near-complete exclusion of the diagnosis FAP among HB patients.  
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HCC is a heterogeneous cancer type in which many etiological factors, geographic differences 
and long-time pathological processes contribute to the development of a malignant tumor (1, 
2). As one of the most important cascades facilitating HCC initiation and progression, 
aberrantly activated Wnt/β-catenin signaling has become a focus for pharmacological 
intervention in recent decades. Although various drugs targeting this signaling pathway have 
been developed and studied in cancers, evidence about the efficiency of these drugs in 
different HCC subgroups is still lacking. In my thesis, using liver cancer cell lines, I aimed to 
identify subgroups of HCCs that may benefit from inhibitors that target β-catenin signaling at 
different cellular levels. 
1. Contribution of mutant β-catenin and AXIN1 to aberrant activation of Wnt/β-catenin-
signaling pathway in HCC progression 
As reported in Chapter 2 and by others, aberrant stimulation of Wnt/β-catenin signaling in 
HCC patients is mainly due to mutations at the CTNNB1 (20%-25%) or AXIN1 (10%) genes (3-
5). The oncogenic CTNNB1 mutations consist of single mutations within exon 3 at the N-
terminal phosphorylation residues, making the protein more resistant to proteolytic 
degradation. For these activating mutations it is well-accepted that they support tumor 
growth by enhancing β-catenin signaling in a dominant fashion. However, whether AXIN1 
mutations also lead to HCC by enhancing β-catenin signaling is still under debate. In AXIN1 
mutant HCCs neither a clear nuclear β-catenin accumulation is observed nor a clear induction 
of β-catenin target genes (4). Similar observations have been made in mice with a liver-specific 
deletion of AXIN1 in which also no clear nuclear β-catenin is detected (6). A potential 
explanation for this apparent lack of β-catenin signaling activation could be functional 
compensation by its homolog AXIN2. In addition, it becomes more complex by multi-function 
roles of AXIN1 regulating the activity of c-Myc (7), p53 (8, 9), Smad3 (10) and interacting with 
other components of centrosome and mitotic spindles (11-14). However, based on our results 
we believe that AXIN1 loss leads to enhanced β-catenin signaling relevant for tumor growth, 
albeit in a less dominant way. Firstly, we observe that all three AXIN1 mutant lines we 
investigated show higher baselines of β-catenin signaling activity by a β-catenin reporter assay, 
indicating β-catenin is actively signaling to the nucleus. The signaling activity is however not 
as high as that in CTNNB1 mutant lines. Secondly, all these AXIN1 mutant lines are impaired 
in their growth following siRNA mediated knockdown of β-catenin, again suggesting that they 
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require some β-catenin signaling to sustain growth. Additionally, another three lines without 
mutations relevant to β-catenin signaling, show induced β-catenin reporter activity resulting 
from siRNA mediated knockdown of AXIN1. 
Hence, although β-catenin is a more powerful driver determining the β-catenin signaling 
activity, the mutated AXIN1 also contributes to the aberrant activation of β-catenin signaling, 
which is important for tumor initiation and progression in particular HCC subgroups. 
2. Alternative treatment for HCC by targeting Wnt/β-catenin-signaling pathway  
Due to difficulties for early detection, most HCC patients are diagnosed at advanced stage. For 
these advanced HCC patients, the current treatment strategy is chemotherapy limited to the 
multi-kinase inhibitor sorafenib. However, treatment with sorafenib promises a minimal 
survival benefit of at most a few months in the majority of HCC patients. Hence, alternative 
treatment options are urgently needed and as explained above targeting the β-catenin 
signaling pathway may represent an attractive option. 
In support of this we observe in our cell line panel a growth reduction of all 9 lines when 
β-catenin levels are reduced using siRNA mediated knock-down. Other studies have provided 
similar results in a limited number of cell lines (4, 15), and by reducing β-catenin levels in 
mouse hepatocarcinogenesis models (16, 17). Which method to choose for reducing β-catenin 
signaling in the clinical setting is however more challenging. Here we first investigated the 
Wnt-secretion inhibitor IWP12. This inhibitor was demonstrated to interfere with Wnt 
secretion and impair the growth of APC and β-catenin mutant CRC cell lines (18). Similarly, our 
study shows that IWP12 reduced growth of most HCC cell lines, which was confirmed by 
knock-down of WLS, a second protein also essential for Wnt secretion. Nevertheless, the 
growth reduction did not result from blocking β-catenin signaling and is also not due to 
alterations in autophagy or ER stress responses. A potential alternative explanation not 
investigated by us, could lie in other functions of Wnt ligands not linked to β-catenin signaling. 
This leads us to the “non-canonical” Wnt signaling pathway, which supports a growth 
suppressive effect (19, 20). Therefore, interfering with the secretion of this subset of Wnt 
ligands is expected to support cellular growth, in contrast to the growth suppression that we 
observed. Another explanation is the mTOR pathway important for cell growth by activating 
ribosome biogenesis and protein synthesis, which is validated to be stimulated by Wnt 
signaling depending on GSK3 instead of β-catenin (21). This suggests that mTOR signaling 
Discussion 
119 
 
could be the mechanism underlying the growth reduction following IWP12 treatment, which 
needs further investigation. 
As a second method to reduce β-catenin signaling, we used tankyrase inhibition. B-
catenin signaling was barely affected following tankyrase inhibition in the CTNNB1 mutant cell 
lines, while it was clearly diminished in all AXIN1 and most non-mutant lines. This indicates 
that in the latter cell lines, tankyrase inhibitor works through regulation of AXIN stability while 
the CTNNB1 mutant lines do not respond, most likely because of the mutant β-catenin 
determining β-catenin signaling activity in a dominant fashion. However, no clear effect on 
cell growth was observed, even in the lines where some reduction in signaling was obtained. 
Based on our data, reduction in β-catenin signaling obtained with either method is 
apparently insufficient to significantly affect the growth of HCC cell lines. This highlights the 
demand of other inhibitors or combinations thereof to achieve optimal effects in the clinic. 
3. Other potential avenues to target Wnt/β-catenin signaling 
Conventional inhibitors targeting Wnt/β-catenin signaling are conservatively designed to 
block the function or interaction of components specifically involved in this pathway. In 
Chapter 5, we identify STRAP as a new player in enhancing Wnt/β-catenin signaling in HCC. 
STRAP has been defined as a scaffold protein participating in a variety of signaling pathways 
in addition to β-catenin. Thus, theoretically blocking the function of STRAP could impair tumor 
growth through multiple avenues. Whether the STRAP protein is druggable remains however 
to be seen, although it will most likely be challenging as there is no enzymatic function that 
can be easily blocked. 
As an active pathway during the embryonic process and carcinogenesis, Wnt/β-catenin 
signaling crosstalks with a number of other signaling pathways. In Chapter 2, we summarized 
that both EGF and FGF pathways are triggered by Wnt/β-catenin signaling, which in turn 
stimulate β-catenin signaling through inhibiting GSK3β activity in HCC development (3). For 
various other pathways including NOTCH (22), NF-κB (23), TGFβ (24) and so on, it has also 
been demonstrated that they interact with Wnt/β-catenin signaling. 
The function of STRAP in regulating Wnt/β-catenin signaling as well as the mutual 
crosstalk between Wnt/β-catenin signaling and other pathways imply a supplementary 
therapeutic approach that synergizes with conventional anti-cancer drugs, to hopefully 
benefit the therapeutic outcomes of HCC patients. 
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4. Future directions 
Although Wnt/β-catenin signaling has been widely investigated and targeted to cure tumors, 
a systematic study about the efficiency of the prevailing inhibitors for HCC treatment is still 
lacking. In this thesis, we started in vitro experiments (cell lines) with two inhibitors. In the 
future, this can also be extended to other reported inhibitors of the pathway, possibly in 
combination with drugs targeting other cellular targets. Based on the data obtained from 
these in vitro studies, in vivo HCC models will also be necessary to evaluate the effect of these 
inhibitors in more physiological conditions. Since the ultimate goal of this study is to 
ameliorate clinical practice for HCC patients, organoids directly derived from tumors will be 
an ideal model for large-scale drug screening to identify the sensitive subgroups to specific 
inhibitors (25). 
  
Discussion 
121 
 
References 
1. Lee SJ, Lim HY. Hepatocellular carcinoma treatment: a comparative review of emerging growth 
factor receptor antagonists. Expert Opin Emerg Drugs 2017;22:191-200. 
2. Marquardt JU, Andersen JB, Thorgeirsson SS. Functional and genetic deconstruction of the 
cellular origin in liver cancer. Nat Rev Cancer 2015;15:653-667. 
3. Wang W, Pan Q, Fuhler GM, Smits R, Peppelenbosch MP. Action and function of Wnt/beta-
catenin signaling in the progression from chronic hepatitis C to hepatocellular carcinoma. J 
Gastroenterol 2017;52:419-431. 
4. Zucman-Rossi J, Benhamouche S, Godard C, Boyault S, Grimber G, Balabaud C, Cunha AS, et al. 
Differential effects of inactivated Axin1 and activated beta-catenin mutations in human hepatocellular 
carcinomas. Oncogene 2007;26:774-780. 
5. Laurent-Puig P, Legoix P, Bluteau O, Belghiti J, Franco D, Binot F, Monges G, et al. Genetic 
alterations associated with hepatocellular carcinomas define distinct pathways of 
hepatocarcinogenesis. Gastroenterology 2001;120:1763-1773. 
6. Feng GJ, Cotta W, Wei XQ, Poetz O, Evans R, Jarde T, Reed K, et al. Conditional disruption of 
Axin1 leads to development of liver tumors in mice. Gastroenterology 2012;143:1650-1659. 
7. Arnold HK, Zhang X, Daniel CJ, Tibbitts D, Escamilla-Powers J, Farrell A, Tokarz S, et al. The Axin1 
scaffold protein promotes formation of a degradation complex for c-Myc. EMBO J 2009;28:500-512. 
8. Rui Y, Xu Z, Lin S, Li Q, Rui H, Luo W, Zhou HM, et al. Axin stimulates p53 functions by activation 
of HIPK2 kinase through multimeric complex formation. EMBO J 2004;23:4583-4594. 
9. Li Q, Lin S, Wang X, Lian G, Lu Z, Guo H, Ruan K, et al. Axin determines cell fate by controlling 
the p53 activation threshold after DNA damage. Nat Cell Biol 2009;11:1128-1134. 
10. Guo X, Ramirez A, Waddell DS, Li Z, Liu X, Wang XF. Axin and GSK3- control Smad3 protein 
stability and modulate TGF- signaling. Genes Dev 2008;22:106-120. 
11. Fumoto K, Kadono M, Izumi N, Kikuchi A. Axin localizes to the centrosome and is involved in 
microtubule nucleation. EMBO Rep 2009;10:606-613. 
12. Kim SM, Choi EJ, Song KJ, Kim S, Seo E, Jho EH, Kee SH. Axin localizes to mitotic spindles and 
centrosomes in mitotic cells. Exp Cell Res 2009;315:943-954. 
13. Ruan K, Ye F, Li C, Liou YC, Lin SC, Lin SY. PLK1 interacts and phosphorylates Axin that is essential 
for proper centrosome formation. PLoS One 2012;7:e49184. 
14. He XQ, Song YQ, Liu R, Liu Y, Zhang F, Zhang Z, Shen YT, et al. Axin-1 Regulates Meiotic Spindle 
Organization in Mouse Oocytes. PLoS One 2016;11:e0157197. 
15. Wang XH, Sun X, Meng XW, Lv ZW, Du YJ, Zhu Y, Chen J, et al. beta-catenin siRNA regulation of 
apoptosis- and angiogenesis-related gene expression in hepatocellular carcinoma cells: potential uses 
for gene therapy. Oncol Rep 2010;24:1093-1099. 
16. Delgado E, Okabe H, Preziosi M, Russell JO, Alvarado TF, Oertel M, Nejak-Bowen KN, et al. 
Complete response of Ctnnb1-mutated tumours to beta-catenin suppression by locked nucleic acid 
antisense in a mouse hepatocarcinogenesis model. J Hepatol 2015;62:380-387. 
17. Tao J, Zhang R, Singh S, Poddar M, Xu E, Oertel M, Chen X, et al. Targeting beta-catenin in 
hepatocellular cancers induced by coexpression of mutant beta-catenin and K-Ras in mice. Hepatology 
2017;65:1581-1599. 
18. Voloshanenko O, Erdmann G, Dubash TD, Augustin I, Metzig M, Moffa G, Hundsrucker C, et al. 
Wnt secretion is required to maintain high levels of Wnt activity in colon cancer cells. Nat Commun 
2013;4:2610. 
19. Yuzugullu H, Benhaj K, Ozturk N, Senturk S, Celik E, Toylu A, Tasdemir N, et al. Canonical Wnt 
signaling is antagonized by noncanonical Wnt5a in hepatocellular carcinoma cells. Molecular cancer 
2009;8:1. 
20. Bi L, Liu X, Wang C, Cao Y, Mao R, Li P, Geng M. Wnt5a involved in regulation of the biological 
behavior of hepatocellular carcinoma. Int J Clin Exp Pathol 2014;7:987-995. 
Chapter 8 
122 
 
21. Inoki K, Ouyang H, Zhu T, Lindvall C, Wang Y, Zhang X, Yang Q, et al. TSC2 integrates Wnt and 
energy signals via a coordinated phosphorylation by AMPK and GSK3 to regulate cell growth. Cell 
2006;126:955-968. 
22. Collu GM, Hidalgo-Sastre A, Brennan K. Wnt-Notch signalling crosstalk in development and 
disease. Cell Mol Life Sci 2014;71:3553-3567. 
23. Ma B, Hottiger MO. Crosstalk between Wnt/beta-Catenin and NF-kappaB Signaling Pathway 
during Inflammation. Front Immunol 2016;7:378. 
24. van den Bosch MH, Blom AB, van Lent PL, van Beuningen HM, Blaney Davidson EN, van der 
Kraan PM, van den Berg WB. Canonical Wnt signaling skews TGF-beta signaling in chondrocytes 
towards signaling via ALK1 and Smad 1/5/8. Cell Signal 2014;26:951-958. 
25. Broutier L, Mastrogiovanni G, Verstegen MM, Francies HE, Gavarro LM, Bradshaw CR, Allen GE, 
et al. Human primary liver cancer-derived organoid cultures for disease modeling and drug screening. 
Nat Med 2017;23:1424-1435. 
  
 
  
  
 
  
 
 
 
Chapter 9 
 
Nederlandse samenvatting 
Dutch summary 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
Dutch Summary 
127 
 
Samenvatting 
Wnt/β-catenine signalering is belangrijk voor de ontwikkeling van alle meercellige organismen 
en is een essentiële regulator van de meeste epitheliale stamcellen. Daarom is het niet 
verrassend dat in vele kankers een foutieve regulatie van Wnt/β-catenine signalering gezien 
wordt (1). Ook in leverkanker wordt veelvuldig een abnormale activatie van deze signaalroute 
gezien, bijvoorbeeld door het verkrijgen van een activerende β-catenine of inactiverende 
AXIN1 mutatie. Behalve door middel van mutaties, kan β-catenine signalering ook door 
diverse andere mechanismen beïnvloed worden. Een voorbeeld zijn de virale eiwitten die tot 
expressie komen tijdens een chronische infectie met HBV of HCV, beide belangrijke 
risicofactoren voor het ontstaan van leverkanker. In hoofdstuk 2 beschrijven we uitgebreid de 
huidige biomedische kennis over de rol van Wnt/β-catenine signalering in de progressie van 
chronische hepatitis C infectie naar levercirrose en leverkanker, en bespreken we in meer 
detail enkele van de mogelijke onderliggende mechanismen. Allereerst benoemen we de 
relatieve mutatie-frequenties van aan β-catenine signalering gerelateerde genen zoals die in 
leverkankercohorten gezien worden. Activerende mutaties in CTNNB1 (coderend voor β-
catenine) zijn de meest voorkomende mutaties resulterend in verhoogd β-catenine 
signalering en dit is vooral het geval in HCV-gerelateerde levertumoren (>25%). Vervolgens 
bespreken we de interactie tussen HCV infectie en Wnt/β-catenine signalering. Zowel het 
virale HCV core als het NS5A eiwit dragen bij aan de activatie van β-catenine signalering. HCV 
infectie is ook geassocieerd met een verhoogde EGFR en FGF signalering. Beide dragen bij aan 
de vorming van cirrose en tumorvorming door middel van het activeren van de PI3K/AKT en 
Ras/Raf/MEK/ERK signaalroutes, maar leiden ook tot een toename in β-catenine signalering. 
Samenvattend, leidt HCV infectie dus via meerdere mechanismen tot een verhoogde β-
catenine signalering. Op zijn beurt draagt de geactiveerde β-catenine signalering bij aan de 
progressie van de initiële hepatitis C infectie naar uiteindelijk cirrose en leverkanker. 
Ondanks de ontwikkeling van een groot aantal moleculaire remmers van β-catenine 
signalering in de afgelopen decennia, is er nog weinig bekend over de effectiviteit van deze 
remmers op leverkankercellen met specifieke genetische mutaties leidend tot een verhoogde 
β-catenine signalering. In hoofdstuk 3 testen we de Wnt secretie remmer IWP12 in ons panel 
van leverkankercellijnen. Allereerst laten we zien dat door middel van siRNA gemedieerde 
knockdown van β-catenine, het overgrote merendeel van de leverkankercellijnen afhankelijk 
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is van β-catenine signalering voor een optimale groei. Het blokkeren van Wnt secretie door 
middel van een behandeling met de porcupine remmer IWP12, vermindert de groei van de 
meeste leverkankercellijnen. Dit effect wordt bevestigd met een knockdown van WLS, wat 
essentieel is voor uitscheiding van Wnt liganden. Geen enkele van de CTNNB1 en AXIN1 
mutante cellijnen wordt echter beïnvloedt op het niveau van β-catenine signalering. Dit laten 
we zien met een β-catenine reporter analyse als ook onveranderde AXIN2 RNA expressie 
niveaus (een betrouwbaar door β-catenine gereguleerd gen) volgend op veranderingen in Wnt 
ligand blootstelling, noch door de Wnt secretie te blokkeren met IWP12 noch met de 
toevoeging van WNT3A ligand. Dit suggereert dat de geexpresseerde oncogene β-catenine en 
mutante AXIN1 eiwitten het signaalniveau op een dominante manier beïnvloeden. Daarnaast 
leidt IWP12 behandeling ook niet tot de inductie van autofagie of endoplasmatisch reticulum 
(ER) stress die mogelijk zou kunnen ontstaan als gevolg van de opstapeling van Wnt ligand in 
het ER. In overeenstemming met ons resultaat hebben anderen laten zien dat knockdown van 
porcupine de groei van verschillende cellijnen verminderd op een Wnt-onafhankelijke manier, 
zonder dat een duidelijke verklaring werd gevonden (2). De meeste darmkankercellijnen die 
we voor diverse analyses ter vergelijking hebben gebruikt, laten een vergelijkbaar resultaat 
zien. Ze zijn afhankelijk van β-catenine signalering en laten een remming in groei zien naar het 
blokkeren van Wnt secretie, zowel m.b.v. IWP12 als WLS knockdown. In overeenstemming 
met de leverkankercellijnen is die groeiremming niet geassocieerd met een duidelijke 
verandering in β-catenine signalering en onafhankelijk van de onderliggende APC of CTNNB1 
mutatie. Onze resultaten suggereren dus dat de meeste darm- en leverkankercellijnen met 
mutaties in de β-catenine signaleringsroute, voor een optimale groei niet sterk afhankelijk zijn 
van extracellulaire blootstelling van Wnt liganden. Het blokkeren van Wnt secretie lijkt echter 
wel bij te dragen aan de remming van tumorgroei via nu nog onbekende mechanismen. 
 In hoofdstuk 4 bestuderen we een tweede categorie van moleculaire remmers van β-
catenine signalering, namelijk de Tankyrase-remmers, en bestuderen we in meer detail de 
bijdrage van AXIN1 en AXIN2 aan β-catenine signalering in leverkanker. Beide eiwitten vormen 
samen met APC en de kinases GSK3 en CK1α, de belangrijkste onderdelen van het β-catenine 
afbraakcomplex. Mutaties in AXIN1 en AXIN2 die tot verlies van functie leiden, worden gezien 
in respectievelijk 10.4% en 3.3% van de levertumoren (3)]. Van deze mutaties wordt verwacht 
dat die leiden tot een verhoogde β-catenine signalering, hoewel dit door enkele publicaties 
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wordt betwist (4-6). De AXIN eiwitten staan zelf ook onder proteolytische controle en worden 
snel afgebroken na poly-ADP-ribosylatie door Tankyrase enzymen. Om die reden zijn 
Tankyrase-remmers in het vizier gekomen als mogelijke therapie omdat hun remming in 
theorie leidt tot stapeling van AXIN, uiteindelijk resulterend in verlaagde β-catenine 
signalering en tumorgroei. In dit hoofdstuk bestuderen we eerst de expressie-niveaus van 
AXIN1 en AXIN2 in ons panel van leverkankerlijnen. Western blot analyse laat zien dat beide 
AXIN eiwitten laag tot expressie komen in de niet-gemuteerde en AXIN1-gemuteerde cellijnen, 
terwijl ze gemakkelijk aan te tonen zijn in de CTNNB1 mutante lijnen. Remming van Tankyrase 
leidde alleen in de CTNNB1 mutante lijnen tot een duidelijk opstapeling van AXIN2. Tot onze 
verrassing was er in geen enkele cellijn een duidelijke stapeling van AXIN1 eiwit aantoonbaar. 
Een mogelijke verklaring is te vinden in de RNA expressie niveaus van beide genen, omdat 
AXIN1 duidelijk lager tot expressie kwam dan AXIN2 in alle cellijnen. Onlangs hebben 
Thorvaldsen et al laten zien dat er een continue aanmaak van nieuw eiwit nodig is voor AXIN 
stapeling (6). Indirect betekent dit dat een hogere AXIN2 RNA expressie zal leiden tot een meer 
robuuste eiwitstapeling, wat in overeenstemming is met onze resultaten. Vervolgens hebben 
we onderzocht in welke mate beide AXIN eiwitten betrokken zijn bij de regulatie van β-
catenine signalering in leverkanker. Hun RNA expressie werd sterk verlaagd m.b.v. siRNA, 
waarbij we APC knockdown als positieve controle gebruikten. Gelijktijdige knockdown van 
beide AXIN genen in de niet-gemuteerde cellijnen liet zien dat beide complementair werken 
in de regulatie van β-catenine signalering. In de AXIN1 mutante lijnen had AXIN1 knockdown 
zoals verwacht geen effect, terwijl AXIN2 knockdown leidde tot een vergelijkbare activatie van 
β-catenine signalering als APC knockdown. Deze resultaten tonen aan dat beide AXIN eiwitten 
betrokken zijn bij β-catenine regulatie in leverkanker, wat in tegenspraak lijkt met publicaties 
die suggereren dat AXIN1 mutaties niet bijdragen aan de groei van leverkanker door het 
activeren van β-catenine signalering (5). Als laatste testen we in dit hoofdstuk of de remming 
van Tankyrases een goede benadering is voor de remming van leverkankergroei. Het niveau 
van β-catenine signalering wordt nauwelijks beïnvloed door Tankyrase remming in de β-
catenine mutante lijnen, terwijl dit duidelijk het geval is in de overige lijnen. Ondanks deze 
remming resulteerde Tankyrase in geen of slechts een minimaal effect op de groei en 
kolonievormings-capaciteit van de behandelde leverkankercellijnen. Deze resultaten 
suggereren dat Tankyrase-remmers waarschijnlijk niet een effectieve behandeling van 
leverkanker zullen vormen.   
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 In hoofdstuk 5 ontdekken we het belang van het oncogene serine-threonine kinase 
receptor associated protein (STRAP) voor het ondersteunen van de groei van leverkanker 
d.m.v. het versterken van β-catenine signalering. STRAP bevat zeven WD40 domeinen en 
wordt beschouwd als een structureel eiwit zonder enzymatische functie die diverse 
regulatoire rollen vervult op een groot aantal cellulaire processen. Gebruikmakend van 
immunohistochemie tonen we een verhoogde STRAP expressie aan in leverkanker, zoals 
eerder ook al aangetoond is voor borst-, long- en darmkanker (7-9). Om de functie van STRAP 
in meer detail te onderzoeken, hebben we siRNA gemedieerde knockdown toegepast op ons 
panel van leverkankercellijnen en knock-out clones gegenereerd m.b.v. CRISPR/Cas9 
genmodificatie. Verlies van het STRAP eiwit resulteerde in een sterk verminderde groei, een 
veranderd celcyclusprofiel en een verminderde capaciteit tot het vormen van kolonies vanuit 
een enkele cel. Daarnaast tonen we aan dat STRAP de β-catenine signalering en daarmee de 
groei van leverkankercellen stimuleert, zowel direct gemeten (verhoogde expressie van door 
β-catenine gereguleerde genen) als indirect (β-catenine signalering gemeten met een 
reporter-analyse). Anderen hebben laten zien dat STRAP aan het katalytische domein van 
GSK3β bindt via zijn WD40 domein en daarmee de capaciteit van GSK3β verminderd om β-
catenine te fosforyleren op de door exon3 gecodeerde N-terminale serine/threonine 
residuen(10, 11). In overeenstemming daarmee zien we verlaagde niveaus van actief β-
catenine in de STRAP knock-out clones van de Huh6 en PLC/PRF/5 cellijnen. Bovendien zien 
we in deze lijnen een vermindering van C-terminale β-catenine fosforylatie op S675, wat naar 
verwachting leidt tot een verminderde rekrutering van transcriptionele co-activatoren (12-14). 
Afwijkend van de β-catenine mutante Huh6 en AXIN1 mutante PLC/PRF/5 cellijn lijkt in Huh7 
geen van deze mechanismen operationeel ondanks een verminderde β-catenine signalering 
na verlies van STRAP expressie. Dit suggereert dat STRAP β-catenine signalering ook via nu nog 
onbekende mechanismen kan beïnvloeden. Een RNA sequentie analyse van STRAP knock-out 
clones en controles suggereert dat STRAP de vernieuwing van stamcellen kan 
vergemakkelijken en tegelijkertijd de differentiatie van cellen kan afremmen. Dezelfde analyse 
laat zien dat behalve β-catenine signalering, diverse andere signaalroutes en metabole 
processen verstoord zijn na het verlies van STRAP expressie, wat in overeenstemming is met 
andere publicaties (15-17). Samenvattend laten onze resultaten zien dat STRAP verhoogd tot 
expressie komt in leverkanker en een groeivoordeel geeft aan de tumorcellen, onder andere 
door het versterken van het β-catenine signaal. 
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 In hoofdstuk 6 bestuderen we hepatoblastomas, een potentieel kwaadaardige vorm 
van leverkanker die vooral bij kinderen voorkomt. De Wnt/β-catenine signaalroute speelt een 
belangrijke rol in het ontstaan van deze tumoren, d.w.z. tussen de 60-80% heeft een 
activerende CTNNB1 mutatie. Hepatoblastomas kunnen echter ook de eerste manifestatie zijn 
van familiaire adenomateuze polyposis (FAP), een erfelijke aanleg leidend tot duizenden dikke 
darmpoliepen en uiteindelijk darmkanker. FAP patiënten dragen een kiembaan APC 
genmutatie die resulteert in verhoogde β-catenine signalering zodra er een somatische 
mutatie ontstaat in het overblijvende wild-type APC allel. Dit is een ernstige ziekte waarbij het 
van groot belang is voor de hepatoblastoma patiënt en gerelateerde familieleden, om FAP in 
een vroeg stadium uit te sluiten. De huidige diagnose is voor een belangrijk deel gebaseerd op 
kiembaan APC mutatie analyse op genomisch DNA, die echter in 10-20% van de gevallen tot 
een fout-negatieve uitslag leidt. In dit hoofdstuk ontwikkelen we en valideren een weefsel-
gebaseerde β-catenine gen en immunohistochemische analyse, die de kiembaanmutatie 
analyse aanvult om de diagnose FAP bij hepatoblastoma patiënten grondig uit te sluiten. Van 
belang voor onze studie is de bevinding dat CTNNB1 en APC mutaties die leiden tot 
tumorvorming, nooit in dezelfde tumor gezien worden. De vondst van een somatische 
activerende exon3 β-catenine mutatie in een hepatoblastoma patiënt betekent dan ook 
meteen dat het risico op FAP sterk verlaagd wordt en gelijk is aan die van de gehele bevolking. 
CTNNB1 mutatie analyse in hepatoblastomas wordt echter bemoeilijkt door het grote aandeel 
(>60%) van genomische deleties, die in grootte kunnen variëren van kleine intra-exonische 
deleties tot grotere, die een deel van exon 2 tot 4 kunnen beslaan. Deze deleties kunnen 
gemakkelijk gemist worden met een routinematige mutatie analyse. In dit hoofdstuk laten we 
zien dat door het combineren van exon3 CTNNB1 mutatie analyse en een 
immunohistochemische vergelijking van totaal en exon3-specifieke β-catenine antilichamen, 
we een betrouwbare diagnose kunnen maken voor het overgrote merendeel van de 
hepatoblastomas. Van de 18 onderzochte monsters, lieten alle drie de FAP-tumoren een wild-
type exon3 sequentie zien en een vergelijkbaar kleurpatroon met beide antilichamen. De 
overige niet-FAP tumoren werden echter gekenmerkt door de identificatie van een missense 
mutatie en een sterk verminderde kleuring met het exon3 specifieke antilichaam, of een 
volledig verlies van kleuring in het geval van exon3 deleties. Als deze methode gecombineerd 
wordt met de routinematige kiembaan APC mutatie analyse, dan kan deze leiden tot een 
nagenoeg volledige uitsluiting van een FAP-diagnose onder hepatoblastoma patiënten.  
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